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Abstract
Alzheimer’s disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions
including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins.
Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical
instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in
transgenic mice after contamination with Alzheimer’s disease brain homogenates, with very limited functional
consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to
transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies
performed any detailed functional assessments. For the first time we demonstrate long term memory and learning
impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human
brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments
(clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by
electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss
using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem
stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions
close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-
positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study
is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of
Alzheimer’s disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a
long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral
inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation
processes.
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Introduction
Alzheimer’s disease is a neurodegenerative disease
characterized by cognitive alterations, cerebral atrophy
[1] and neuropathological lesions including neuronal
loss [2], accumulation of misfolded and aggregated β-
amyloid peptide and tau proteins [3]. Patients exposed
to cadaver-derived hormones, dural grafts or to
surgical instruments, presumably contaminated with
β-amyloid peptide (Aβ), have a higher risk of develop-
ing early-onset Aβ pathology than non-exposed sub-
jects [4–6]. Experimental induction (or acceleration)
of β-amyloidosis or tauopathy has been described in
rodents after intracerebral and even peripheral con-
tamination with pathological Aβ or tau-bearing brain
homogenates [7, 8]. However, none of the long-term
transmission studies with Aβ or tau-positive inocula
provided evidence for pronounced cognitive decline or
neurodegeneration [9]. Aged non-human primates can
naturally develop β-amyloid lesions [10] and a long-
term study in marmosets demonstrated induction of
sparse β-amyloidosis 3.5 to 7 years post-inoculation,
but there was no evidence of cognitive decline,
neurodegeneration, functional Alzheimer’s disease
hallmarks, or other clinical signs [11]. This calls for
additional clinical analysis in primates after inocula-
tion with Alzheimer’s disease brain homogenates.
Here, we used a multimodal approach, including non-
invasive methods, to evaluate the impact of inoculation of
human Alzheimer’s disease-brain homogenates on both
brain function and integrity in mouse lemur primates
(Microcebus murinus). These small primates (body length:
12 cm; weight: 60-120 g) have a maximal lifespan of 12
years in our colony [12], although longer lifespans have
been reported in some breeding colonies [13, 14], and are
considered to be “old” after 6 years [12]. Mouse lemurs are
widely used models to study human aging [15] since they
display age-related alterations of their sensorial system,
motor functions, biological rhythms, and immune and
endocrine systems [12]. Their cerebral aging profile is simi-
lar to that of humans, as some can display age-related cog-
nitive alterations associated with cerebral atrophy [16]. Like
humans and other non-human primates, they are genetic-
ally heterogeneous, providing a natural diversity of aging
profiles. In addition, genes associated with β-amyloidosis,
such as amyloid precursor protein (APP), are similar in
humans and mouse lemurs [17]. They can develop intracel-
lular deposits of APP/Aβ [18, 19], as well as β-amyloid pla-
ques which can be detected in 25% of the animals over 8
years of age [20, 21], as well as tauopathy [21, 22]. Finally,
their small size and reduced lifespan (compared to ma-
caques) facilitates the creation of experimental cohorts to
evaluate factors that modulate cerebral aging.
Human brain homogenates from Alzheimer’s disease
or control patients were inoculated in the brain of 12
adult mouse lemurs. We performed longitudinal cogni-
tive assessments, electroencephalography (EEG), and
morphological magnetic resonance imaging (MRI) stud-
ies up to 18months post-inoculation (mpi), followed by
immunohistopathological examination of brain tissues.
In parallel, transgenic mice were also inoculated to as-
sess the pathological potential of our homogenates. The
inoculation of Alzheimer’s disease-brain homogenates in
primates induced an encephalopathy characterized by
pronounced cognitive, functional, and morphological al-
terations, as well as neuronal loss. Most alterations were
not seen 6 mpi but became evident at 12 mpi, ruling out
immediate pathogenicity of the homogenates. Sparse β-
amyloid and tau lesions were also detected in the brains
of Alzheimer’s disease-inoculated mouse lemurs at the
inoculation sites and spreading from the inoculation
sites could be highlighted in some animals, but these le-
sions were never detected in control animals. These re-
sults show that inoculation of Alzheimer’s disease brain
homogenates induces a pathology leading to cognitive
impairments, clinical signs, neuronal loss and alteration
of neuronal activity in a primate.
Materials and methods
Human brain samples
Frozen brain tissue samples (parietal cortex) from two
Alzheimer’s disease patients (Braak and Braak stage VI,
Thal stages 5 and 4, respectively) and one control indi-
vidual (Braak and Braak/Thal stages 0) were obtained
from brains collected in a brain donation program of
the GIE NeuroCEB Brain Bank run by a consortium of
Patient Associations: ARSEP (French association for re-
search on multiple sclerosis), CSC (cerebellar ataxias),
France Alzheimer, and France Parkinson, with the sup-
port of the Fondation Plan Alzheimer and IHU A-ICM
(Additional file 1: Table S1). The consent forms were
signed by either the patients themselves or their next of
kin in their name, in accordance with French bioethics
laws. The GIE NeuroCEB Brain Bank has been declared
at the Ministry of Higher Education and Research and
has received approval to distribute samples (agreement
AC-2013-1887).
These brain tissues were first assessed by immunohis-
tochemistry. They were cut into 4-μm-thick paraffin
sections. Sections were deparaffinized in xylene, succes-
sively rehydrated through ethanol (100, 90, and 70%),
and finally rinsed under running tap water for 10 min.
They were then incubated in 99% formic acid for 5 min,
washed again under running tap water, quenched for
endogenous peroxidase with 3% hydrogen peroxide and
20% methanol, and finally washed in water. Sections
were then blocked by incubating the sections at room
temperature for 30 min in 4% bovine serum albumin
(BSA) in 0.05 M tris-buffered saline, with 0.05% Tween
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20, pH 8 (TBS-Tween, Sigma). They were then incu-
bated overnight at + 4 °C with the 6F3D anti-Aβ anti-
body (Dako, Glostrup, Denmark, 1/200), polyclonal
anti-tau antibody (Dako, Glostrup, Denmark, 1/500),
and monoclonal anti-alpha-synuclein (LB509, Zymed,
USA, 1/250) routinely used for the detection of β-
amyloid, tau and alpha-synuclein deposits, respectively.
The sections were further incubated with a biotinylated
secondary antibody (25 min at room temperature), and
the presence of the secondary antibody revealed by
streptavidin–horseradish peroxidase conjugate using
diaminobenzidine as chromogen (Dako, Glostrup,
Denmark), after which they were counterstained with
Harris hematoxylin.
Preparation of human brain homogenates and
biochemical analysis
Parietal cortex samples were individually homogenized
at 20% weight/volume (w/v) in a sterile 5% glucose
solution (Virbac, Boulogne, France) in a ribolyser sample
homogenizer (Hybaid, FastPrep FP120, Bio 101, Thermo
Savant). Brain homogenates were then aliquoted into
sterile polypropylene tubes and stored at − 80 °C until
use.
Brain homogenates were further characterized by bio-
chemistry. For Aβ, brain 20% homogenates were diluted
in 6.8M guanidine and 68mM TrisHCl to obtain a final
concentration of 5M guanidine, protease inhibitor
(Complete Mini, Sigma Aldrich, MO, USA) added, and
vortexed for 3 h at room temperature. Aβ immunoquanti-
fication was performed in duplicate with human Aβ1–42
ELISA kits (Invitrogen, Carlsbad, CA, USA) and Aβ1–40
ELISA kits (Invitrogen) according to the manufacturer’s
instructions. For tau characterization, brain homogenates
were sonicated on ice for 5 min, centrifuged for 5min at
3000 x g at + 4 °C, diluted in 20mM Tris/2% SDS and
sonicated on ice for 5min. Samples were diluted to 1 μg/
μL, diluted in 2X lithium dodecyl sulfate (LDS, Thermo
Fisher Scientific, Villebon sur Yvette, France) buffer with
reducers, and heated at + 100 °C for 10min. Ten μg of
samples were loaded on Criterion gels (Biorad, Hercules,
CA, USA) and migrated in MOPS buffer for 90min at
165 V on ice. After protein transfer on nitrocellulose
sheets, either pS396 (Life technologies, Carlsbad, CA,
USA) or tau-Cter antibodies [23] were incubated over-
night at + 4 °C. A peroxidase coupled secondary anti-
rabbit antibody (ref-23817-2, Biovalley, Nanterre, France)
was then applied for 45min at room temperature.
Immunoblotting (or western blotting) was revealed by
ECL. GAPDH (ref sc-25778, Santacruz, Nanterre, France)
was used as a loading control. Operators were blinded to
the status of the patients. Brain homogenates were also
characterized for the presence of prion proteins by west-
ern blotting. Fragments from frontal cortex and
cerebellum were homogenized in an isotonic glucose solu-
tion. Scrapie-associated fibrils were purified after digestion
by proteinase K. Polyacrylamide gel electrophoresis was
performed and PrPres was evaluated with 3F4 (Signet,
0.04 μg/ml) antibodies and revealed by electrochemolumi-
nescence. Tau was characterized by western blotting using
pS396 (Life technologies, Carlsbad, CA, USA) or tau-Cter
antibodies [23]. Brain homogenates were also character-
ized for the presence of Prion proteins by western blotting
according to protocols routinely used in the GIE
NeuroCEB Brain Bank.
Ethical statement for animal experiments
All animal experiments were conducted in accordance with
the European Community Council Directive 2010/63/UE.
Animal care was in accordance with institutional guidelines
and experimental procedures were approved by local
ethical committees (authorizations 12–089; ethics commit-
tees CEtEA-CEA DSV IdF N°44, France, and agreement
APAFIS#2264–2015101320441671 from CEEA75, Lille,
France).
Animals and overall experimental plan
Experiments were conducted on 12 middle-aged mouse
lemurs (age = 3.5 ± 0.2 years; males were used in the
study as, in our colony, females are reserved for
breeding). They were all born and bred in a laboratory
breeding colony (UMR 7179 CNRS/MNHN, France;
European Institutions Agreement #962773). Mouse le-
murs were maintained at a constant temperature of
24–26 °C and relative humidity of 55% and were housed
in individual cages with an enriched environment
(jumping and hiding). Seasonal lighting (summer: 14 h
of light/10 h of dark; winter: 10 h of light/14 h of dark)
was applied to coincide with the seasonal rhythm of the
animals. Their diet consisted of fresh apples and a
homemade mixture of banana, cereals, eggs, and milk
and animals had free access to tap water. Before enter-
ing the study, all animals were examined for health and
given an ophthalmological examination. None of them
were previously involved in pharmacological trials or
invasive studies. The experiment was based on the
inoculation of human brain homogenates from
Alzheimer’s disease patients (AD-inoculated group) or
a control subject (CTRL-inoculated group) into the
brains of mouse lemurs (n = 6 animals per group).
Group assignments of the animals were performed to
obtain two homogeneous groups based on pre-
inoculation learning abilities. Longitudinal behavioral,
EEG, and morphological MRI studies were performed
up to 18 mpi, followed by immunohistopathological ex-
aminations of brain tissues (age at death = 5.0 ± 0.2
years, Additional file 1: Table S2), with investigators
blind to the group assignment when assessing these
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outcomes. Five year-old mouse lemurs are considered
middle-aged and they usually do not display cerebral at-
rophy, β-amyloid or tau lesions. We chose to inoculate
young adults (3.5 ± 0.2 years) and to follow them during
18 months when they reached a middle-aged stage (age
at euthanasia around 5 years) in order to avoid any
drawback linked to aging that could affect cerebral at-
rophy and/or neuropathological status. Two control-
inoculated animals were euthanized for ethical reasons
at 12 mpi due to an abdominal infection following self-
removal of abdominal sutures after wireless telemetry
transmitter explantation. These animals were thus not
evaluated by MRI at 12, 15, or 18 mpi or for behavioral
studies at 18 mpi.
Mouse experiments were performed in eight-week-old
APP/PS1dE9 mouse model of β-amyloidosis (n = 21) [24]
and five-week-old Tau30+/+ mouse model of tauopathy
(n = 15) [25]. The same brain homogenates as those used
in lemurs were inoculated in the mice. APP/PS1dE9 mice
were followed-up for 4 months, while Tau30+/+ mice
were followed-up for 1 month before immunohisto-
pathological examinations of their brains.
Stereotaxic injections in mouse lemurs
In mouse lemurs, brain homogenates were injected using
stereotaxic surgery in four different sites surrounding the
parietal cortex in order to spread the homogenates in wide
brain regions. The 20% aliquoted homogenates were diluted
to 10% (w/v) in sterile Dulbecco’s phosphate-buffered saline
(PBS, Gibco, ThermoFisher Scientific, France) extemporan-
eously. Six animals received brain extract from the control
patient (CTRL-inoculated group) and six received brain ex-
tract from Alzheimer’s disease patients (n = 3 per patient,
AD-inoculated group). Animals were fasted the day before
surgery. Pre-anesthesia (atropine, 0.025mg/kg, subcutane-
ous injection) was performed 30min before anesthesia
(Isoflurane, Vetflurane, 4.5% for induction and 1–2% for
maintenance) as described previously [26]. Animals were
then placed in a stereotaxic frame (Phymep, France). Burr
holes were drilled 1.25mm in front of the interaural axe.
Using 26-gauge needles, 6.5 μL of 10% w/v brain homoge-
nates were injected bilaterally (L +/− 2.5mm) 3mm below
the brain surface. Homogenates were inoculated at 1 μL/
min. Needles were kept in place for additional 2min before
they were slowly moved 2mm above where bilateral injec-
tions were also performed (same volume and injection
speed as described above). Needles were kept in place for
additional 5min before being slowly removed. Respiration
rate was monitored during the entire procedure and body
temperature was maintained at 37 ± 0.5 °C with a heating
blanket or air-heating system. The surgical area was cleaned
before and after surgery (iodinate povidone, Vetedine,
Vetoquinol, France), the incision sutured, and the animals
were placed in an incubator at 25 °C and monitored until
recovery from anesthesia. Mouse lemurs were followed up
to 18months after inoculation (Additional file 1: Table S2).
Stereotaxic injections in mice
Control- or Alzheimer’s disease-brain homogenates
(prepared identically to those injected into the mouse
lemurs) were injected bilaterally in the dorsal
hippocampus (AP − 2 mm, DV − 2 mm, L +/− 1mm
[27]) of eight-week-old female APP/PS1dE9 mice (n = 21)
and five-week-old Tau30+/+ mice (n = 15) of both sexes.
Mice were randomly assigned to control- (APP/PS1ΔE9:
n = 6 and Tau30+/+: n = 5) or Alzheimer’s disease-
inoculated groups (APP/PS1ΔE9: n = 6 and 9 per patient,
Tau30+/+: n = 5 per patient). They were anaesthetized by
intraperitoneal ketamine-xylazine injection (Imalgène
1000, Merial, France (1 mg/10 g); 2% Rompun, Bayer
Healthcare, Leverkusen, Germany (0.1 mg/10 g)) and
placed in a stereotaxic frame (Phymep, France).
Respiration rate was monitored and body temperature
was maintained at 37 ± 0.5 °C with a heating blanket dur-
ing surgery. After making a midline incision of the scalp,
burr holes were drilled in the appropriate location.
Bilateral intrahippocampal injections of 2 μL 10% brain
homogenates were performed with a 26-gauge needle.
The surgical area was cleaned before and after surgery
(iodinate povidone, Vetedine, Vetoquinol, France), the
incision sutured, and the animals placed in an incubator
(temperature 25 °C) and monitored until recovery from
anesthesia.
Behavioral evaluations
Accelerating rotarod task
Mouse lemurs were evaluated with the accelerating
rotarod task (model 7750, Ugo Basile, Italy) before
inoculation and every 6 mpi. Animals were placed on a
5-cm-diameter rotating cylinder turning at 20 rotations
per minute (rpm). The rod then accelerated steadily up
to 40 rpm until the end of the test, which was reached
when the animal fell or gripped onto the rod during at
least three consecutive turns without stabilizing its bal-
ance. Latency to fall off or grip the rod was recorded
for each trial. Animals underwent five consecutive trials
and the best result was recorded with values expressed
in seconds. The apparatus was cleaned with ethanol be-
tween each trial and each animal.
Visual discrimination test
The cognition of mouse lemurs was evaluated in an
apparatus (Additional file 2: Figure S1a) adapted from the
Lashley jumping stand apparatus [28], which is a vertical
cage made of plywood walls, except for the front panel,
which is a one-way mirror allowing observation. Two dis-
crimination tasks were performed: a learning task and a
long-term memory task. These tests involved a succession
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of visual discrimination tasks during which the mouse
lemur had to jump from a heightened central platform to
one of two lateral boards, one of which allowed access to
a reinforcing chamber containing a positive reward (the
possibility of reaching a safe nestbox for a 2-min rest). As
mouse lemurs prefer confined spaces, reaching a nest
when placed in an open space is a strong motivator for be-
havioral testing. If no jump is performed within 1min, the
central station can be progressively and gently tilted
downwards creating a slippery slope, encouraging the
mouse lemur to jump. Boards can be covered with remov-
able and easily-discriminable patches of varied shape,
texture, and pattern (i.e. visual discrimination clues). Each
board can be locked in a stable position or unlocked to be-
come unstable and fall if a lemur jumps on it. For a pair of
patches, one is always associated with the stable board,
giving access to the nest (positive result), and the other
with the unstable board that falls when the lemur jumps
on it (negative result). During a discrimination task, the
mouse lemur had to identify the positive stimulus which
signaled access to the nest. Left/right locations of the
stimuli were randomly alternated during the attempts with
the restriction of no more than three consecutive trials in
the same configuration. Testing continued until a success
criterion - defined as eight correct choices out of 10 suc-
cessive attempts - was achieved. Before the first test, le-
murs underwent a habituation session composed of seven
trials. For the first four trials, only one fixed central board
was attached just below the nestbox opening. In trial 1, a
cylindrical rod connected the central station to the board
so that no jump was required to reach the nestbox. In trial
2, the rod was removed so that the mouse lemur had to
jump onto the central board to access the nestbox. In tri-
als 3 and 4, an opaque vertical screen was added above
the middle of the board masking the nestbox opening.
The mouse lemur had to jump onto the board and then
walk under the screen to access the nestbox. For the final
three trials, the fixed landing platform was placed
alternately to the left or right of the nestbox opening
which was masked by the opaque screen. After the habitu-
ation session, mouse lemurs underwent the first discrim-
ination learning task – distinguishing between a pair of
patches – to test their learning abilities. This task was per-
formed before inoculation and then at 6, 12, and 18 mpi
with a new set of discrimination task stimuli each time
(i.e. a new pair of patches). Long-time retention was also
evaluated at the three post-inoculation time points
through recall of the discrimination task from 6 months
prior (Additional file 2: Figure S1b).
Electroencephalography (EEG)
EEG studies were conducted in mouse lemurs using tele-
metric devices as described before [29, 30]. Animals re-
ceived pre-anesthesia (5mg/mL Diazepam, Roche, France,
intramuscular injection of 200 μL/100 g) and were then
anesthetized with isoflurane. A wireless telemetry trans-
mitter (2.5 g, PhysioTel F20-EET, Data Science, St Paul,
MN, USA), equipped with simultaneous recording for one
EEG and one electromyogram (EMG) channel (1–500Hz
sampling rate), was implanted in the abdominal cavity.
The electrode leads were threaded subcutaneously from
the abdomen to the skull. Electrodes were placed on the
dura mater of the anterior frontal cortex according to a
stereotaxic atlas of the mouse lemur brain and secured
using dental cement [31]. The frontal cortex, and not the
parietal cortex in which brains homogenates were inocu-
lated, was chosen for this evaluation to focus on the im-
pact of the brain homogenate inoculation on cerebral
networks, including those distant from the inoculation
site. For EMG recording, bipolar electrodes were sutured
into the neck muscles using non-absorbable polyamide
sutures. Animals were monitored for respiration rate and
body temperature during surgery, observed until
anesthesia recovery, and allowed to recover from surgery
for 1 week before recording. EEG and EMG data were
continuously collected using PC running Dataquest soft-
ware (Data Science International, St Paul, MN, USA)
linked to a receiver base (RPC-1, Data Science, St Paul,
MN, USA), placed on the floor of the home cage inhabited
by the implanted animals. Electrodes and the telemetry
transmitter were removed after 1 week of recording under
the same surgical conditions as for implantation. The EEG
data were analyzed with Neuroscore v2.1.0 (Data Science
International, St Paul, MN, USA). Analysis focused on the
active state, determined by locomotor activity recording
(included in the telemetry data of EMG recordings). EEGs
were performed before inoculation and 6 and 12 mpi. We
focused on delta (0.5–4Hz), theta (4–8Hz), alpha (8–12
Hz), sigma (12–16Hz), and beta (16–24Hz) frequency
waves. At each time point, each wave was normalized ac-
cording to mean values of the control-inoculated animals.
The operator was blinded to the group attribution during
EEG signal processing.
Morphological MRI
Brain images were recorded on a 7.0 Tesla spectrometer
(Agilent, USA) using a four-channel phase surface coil
(RapidBiomedical, Rimpar, Germany) actively decoupled
from the transmitting birdcage probe (RapidBiomedical,
Rimpar, Germany). Two-dimensional fast spin-echo im-
ages were recorded with an isotropic nominal resolution
of 230 μm (128 slices, TR/TE = 10000/17.4 ms, rare fac-
tor = 4; field of view = 29.4 × 29.4 mm2, matrix = 128 ×
128, slice thickness = 230 μm, acquisition time = 32min).
MR images were zero-filled to reach an apparent iso-
tropic resolution of 115 μm. Animals were anesthetized
and monitored as described for stereotaxic injections.
MR images were recorded for each animal before
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inoculation, 15 days after inoculation and then every 3
months until 18 mpi.
Images were analyzed using voxel-based morphom-
etry by applying SPM8 (Wellcome Trust Institute of
Neurology, University College London, UK, www.fil.
ion.ucl.ac.uk/spm) with the SPMMouse toolbox (http://
spmmouse.org) for animal brain morphometry [32].
Fifteen-day post-inoculation images were not included
in this analysis, as they were only used to ensure accur-
ate injection cannula placement and the lack of acute
lesions following surgery.
The brain images were segmented into gray (GM) and
white matter (WM) tissue probability maps using locally
developed priors, then spatially transformed to the
standard space, defined by Sawiak et al., using a GM
mouse-lemur template [32]. Affine regularization was set
for an average-sized template, with a bias non-
uniformity FWHM cut off of 10 mm and a 5 mm basis-
function cut off and sampling distance of 0.3 mm. The
resulting GM and WM portions were output in rigid
template space, and DARTEL [33] was used to create
non-linearly registered maps for each subject and com-
mon templates for the cohort of animals. The warped
GM portions for each subject were adjusted using the
Jacobian determinant from the DARTEL registration
fields to preserve tissue amounts (“optimized VBM”
[34]) and smoothed with a Gaussian kernel of 600 μm to
produce maps for analysis.
A general linear model was designed to evaluate rela-
tive changes in GM values as a function of time between
the control- and Alzheimer’s disease-inoculated groups.
Longitudinal follow-up of each animal was considered in
the design matrix, and total intracranial volumes were
treated as covariates of no interest. This type of analysis
produces t-statistic and color-coded maps that are the
product of a statistical analysis performed at every voxel
in the brain. Contiguous groups of voxels that attain
statistical significance, called clusters, are displayed on
brain images.
With the general linear model, if the brain of one ani-
mal is defined by the number “j”, and the location of a
pixel is defined as “k”. The signal within a pixel (Ykj Þ can
be explained by the following equation
Ykj ¼ x j;1βk1 þ x j;2βk2 þ T 1jβk3 þ T 2jβk4 þ…þ T 6jβk8
þ T 7jβk9 þ…þ T12j βk14 þ TIV jβk15 þ ϵkj
With βk1 = Alzheimer’s disease brain inoculation ef-
fect (n = 42 images); βk2 = control brain inoculation
effect (n = 36 images); βk3 = Longitudinal follow-up
for Alzheimer’s disease-brain inoculated animal #1
(n = 7 values, i.e. at 0, 3, 6, 9, 12, 15, and 18 mpi);
βk4 = Longitudinal follow-up for Alzheimer’s disease-
brain inoculated animal #2 (n = 7 values, i.e. at 0, 3,
6, 9, 12, 15, and 18 mpi);...; βk8 = Longitudinal
follow-up for Alzheimer’s disease-brain inoculated
animal #6; βk9 = Longitudinal follow-up for control
animal #1;…; βk14 = Longitudinal follow-up for con-
trol animal #6; …; βk15 = total intracranial volume
(TIV) for each animal. The Alzheimer’s disease-brain
inoculation effect is defined by x j;1β
k
1 and the
control-brain inoculation effect is defined by x j;2β
k
2 .
Thus, if the image corresponds to an Alzheimer’s
disease-inoculated animal, xj, 1 = 1 and xj, 2 = 0, if the
image corresponds to a control-inoculated animal, xj,
1 = 0 and xj, 2 = 1. T
x
j is the time post-inoculation for
each animal x. Otherwise, Txj ¼ 0 . TIV corresponds
to the total intracranial volume value for each ani-
mal. It was similar for the different images from the
same animal followed-up longitudinally. The term ϵkj
corresponds to the “error” of the measure for each
animal.
As an example, on the basis of this model, for
image 1 of animal 1 (Alzheimer’s disease group,
image before inoculation ( T 11 ¼ 1 )): Yk1 ¼ βk1 þ 1 βk3
þTIV 1βk15 þ ϵk1 ; for image 2 of animal 1 (Alzheimer’s
disease group, image at 3 mpi (T 12 ¼ 3 months ¼ 92
days)): Yk2 ¼ βk1 þ 92 βk3 þ TIV 2βk15 þ ϵk2 ; for image 3 of
animal 1 (Alzheimer’s disease group, image at 6 mpi
( T 13 ¼ 6 months ¼ 183 days)): Yk3 ¼ βk1 þ 183 βk3
þTIV 3βk15 þ ϵk3 … for image 1 from animal 7 (control
group image before inoculation (T 743 ¼ 1)):): Yk43 ¼ βk2
þ1 βk9 þ TIV 43βk15 þ ϵk43 ; for image 2 of animal 7
(control group image at 3 mpi (T 744 ¼ 3 months ¼ 92
days)): Yk44 ¼ βk2 þ 92 βk9 þ TIV 44βk15 þ ϵk44.
A contrast defines a linear combination of β as cTβ. For
example, the test evaluating whether the probability of
pixels from animals inoculated with Alzheimer’s disease-
brains to be GM is lower than that for control-brain inocu-
lated animals is defined using a contrast cTβ = {− 1 1 0...]T.
The Null hypothesis is H0 : c
Tβ = 0, whereas the alternative
hypotheses is H1 : c
Tβ > 0. This hypothesis is tested with:
T ¼ c
Tβ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σ2cT XTX
 −1
c
q ¼ contrastﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
estimated variance
p
This analysis allows the removal of confounding ef-
fects, such as repetition of the measures during longitu-
dinal evaluation of the same animal (i.e. βk3 , β
k
4 ,…, β
k
8 , β
k
9
,…, βk14) or TIV (β
k
15) from the raw data. In other words,
volumetric scans were entered as the dependent variable.
The treatment groups of the animals (Alzheimer’s
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disease or control-brain inoculation) were the independ-
ent variables. Longitudinal follow-up effect and TIV
were covariates.
One-tailed t-test contrasts were set up to find areas in
which probability values from GM maps were different
in Alzheimer’s disease and control-brain inoculated ani-
mals (i.e. cTβ = {−1 1 0...]T or {1–1 0...]T contrasts). To
control for multiple comparisons, an adjusted p-value
was calculated using the voxel-wise false discovery rate
(FDR-corrected p < 0.05), with extent threshold values of
10 voxels, meaning that clusters required 10 contiguous
voxels to be selected as relevant [35]. Voxels with a
modulated GM value below 0.2 were not considered for
statistical analysis. The operator was blinded to the
group attribution during image processing.
The rate of atrophy evolution over time was then fur-
ther evaluated based on changes of the Jacobian deter-
minant. More specifically, the change in the Jacobian
determinant was calculated for each subject relative to
baseline and averaged groups, yielding mean volume
changes from baseline to time t post-inoculation of Δ
J
ADðtÞ and Δ JCTRLðtÞ for Alzheimer’s disease- and
control-inoculated groups, respectively. Subtracting
these highlighted voxels showing differential atrophy be-
tween groups at each stage. We evaluated differences in
atrophy over the first 6 months, further atrophy that oc-
curred from six to 12months, and later atrophy occur-
ring from 12 to 18months: i.e. Δ J
ADð6Þ−Δ JCTRLð6Þ ,
ðΔ JADð12Þ−Δ JCTRLð12ÞÞ−ðΔ JADð6Þ−Δ JCTRLð6ÞÞ and ðΔ
J
ADð18Þ−Δ JCTRLð18ÞÞ−ðΔ JADð12Þ−Δ JCTRLð12ÞÞ.
Immunohistochemistry and biochemistry
Five mouse lemurs from each group were studied by im-
munohistochemistry. The last animal from each group
was not evaluated by immunohistochemistry as its brain
was sampled for future inoculations in new cohorts of
animals (second passages). All mice were included in im-
munohistochemical analyses. Each animal studied by im-
munohistochemistry was euthanized with an overdose of
sodium pentobarbital (100mg/kg intraperitoneally)
followed by intracardiac perfusion with 4% paraformal-
dehyde in PBS. After overnight post-fixation, brains were
cryoprotected using 15 and 30% sucrose solutions. Brain
coronal sections (40-μm-thick) were cut on a sliding
freezing microtome (SM2400, Leica Microsytem).
Twenty series of sections were performed. The floating
histological serial sections were preserved in a storage
solution (30% glycerol, 30% ethylene glycol, 30% distilled
water, and 10% phosphate buffer) at − 20 °C until use.
Serial sections of the entire brains of mouse lemurs
were used for Aβ (4G8), tau (AT8, MC1, and AT100),
glial fibrillary acidic protein (GFAP), and neuronal
nuclei (NeuN) using immunohistochemistry. One
series of sections (i.e. one section every 20th sections,
which represents approximately 12 sections) was used
for each staining, except for NeuN that used 4 series
(i.e. one section every 5th sections). Monoclonal anti-
body AT8 (Thermo Scientific MN1020B, USA)
recognizes phosphorylated residues serine 202 and
threonine 205 of Tau. The monoclonal antibody
AT100 (Thermo Scientific MN1060, USA) recognizes
phosphorylated residues threonine 212 and serine 214
of Tau. The monoclonal antibody MC1 was a generous
gift from Peter Davies and recognizes conformational
changes in residues seven to nine and 313–322.
Human sections were used as positive controls. Free-
floating sections were rinsed in 0.1 M PBS and incu-
bated in 0.3% hydrogen peroxide for 20 min. For 4G8
staining, sections were pre-treated with 80% formic
for 2 min. Pre-treatment with PBS - Triton 0.5%
(Triton X-100, Sigma Aldrich, MO, USA) and 3% bo-
vine serum albumin (BSA) blocking was performed at
+ 4 °C for 30 min before a 2 day-incubation with either
biotinylated 4G8 (Covance, NJ, USA, 1/250), GFAP
(Dako, Denmark, 1/5000), or NeuN (Abcam,
Cambridge, UK, 1/2000) antibodies. Sections stained
for tau lesions were pre-treated with 1x Citrate Buffer,
in a 100 °C water bath for 30 min for antigen unmask-
ing. Then they were processed with PBS - Triton 0.2%
(Triton X-100, Sigma Aldrich, MO, USA) and 10%
normal goat serum (NGS) 10% blocking at + 4 °C for 1
h before a 3 day-incubation at 4 °C with AT8 (1/500 in
PBS - Triton 0.2% and NGS 5%), MC1 (1/500 in PBS -
Triton 0.2% and NGS 5%) or AT100 (1/200 in PBS -
Triton 0.2% and NGS 5%). Sections were incubated in
biotinylated anti-mouse or anti-rabbit secondary anti-
bodies (IgG, Vector Laboratories, Burlingame, CA,
USA) in PBS - Triton 0.2% for 1 h before revelation.
The ABC Vectastain kit (Vector Laboratories,
Burlingame, CA, USA) was used to amplify DAB
revelation (DAB SK4100 kit, Vector Laboratories,
Burlingame, CA, USA). Sections stained for Tau were
also counterstained with cresyl violet for 45 s or coun-
terstained with Olig2 (Millipore AB9610, USA, 1/500)
to detect oligodendrocytes. Images of stained serial
sections were digitized with an Axio ScanZ.1 slide
scanner (Zeiss, Jena, Germany) at X20 (0.22 μm in
plane resolution). The scanned files were exported as
jpeg RGB images with a 30% compression (0.73 μm in
plane resolution) using Zen 2.0 (Zeiss, Jena,
Germany).
Quantification of intracellular APP/Aβ deposits was
performed blind using 4G8 stained-sections and ImageJ
1.52b (https://imagej.nih.gov/ij/). Briefly, 4G8-positive
objects were segmented using the same threshold for
each animal. Then masks were created to exclude brain
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vessels from parenchyma. Overlap between 4G8-positive
objects and these masks was used to evaluate 4G8-
positive staining either in brain parenchyma (ImageJ
ROI manager and analyze particles function). Three
brain regions (caudate nucleus, putamen, and hippocam-
pus) were studied. Quantification of GFAP-stained sec-
tions was blindly performed using ImageJ 1.52b. Each
structure (frontal cortex, entorhinal cortex, amygdala,
hippocampus, posterior cingulate, and retrosplenial cor-
tices) was manually defined for both hemispheres. GFAP
staining density was evaluated as relative optical density
(log (255/(255-GFAP gray level))) in each structure.
Microglial reaction was further evaluated in mouse
lemurs by Western blot analysis. Proteins were ex-
tracted from two floating brain sections from each
mouse lemur, taken at the level of the inoculation site
(Qproteome FFPE – Tissue Extraction Buffer, Qiagen).
Extracted total proteins were detected by immuno-
blotting using SDS–PAGE (Criterion TGX Stain-Free
Precast Gel 4–20%, Bio-Rad), UV activation, nitrocel-
lulose membrane transfer (Trans-Blot Turbo RTA
Transfer Kit, Bio-Rad) and by blotting with anti-Iba1
rabbit polyclonal antibody (Wako, 1:1000) followed by
anti-rabbit secondary antibody (Invitrogen, 1:5000)
and by Clarity Western ECL chemiluminescence reve-
lation (Bio-Rad). Proteins were migrated together with
a molecular weight marker (Precision Plus Protein
Standards Unstained, Bio-Rad) ranging from 10 to
250 kD. Images of the blots were digitized with a
ChemiDoc Imaging System (Bio-Rad) and quantified
with the Image Lab Software 5.2.1 (Bio-Rad).
Serial sections of the entire brain of APP/PS1ΔE9 mice
were stained for the evaluation of Aβ pathology, as well
as inflammation (Iba1 and GFAP). Brain sections were
rinsed with PBS, and then incubated in 0.3% hydrogen
peroxide for 20 min. Sections were then blocked with
PBS-0.5% Triton (Triton X-100, Sigma, St Louis, MO,
USA) and 4.5% normal goat serum (NGS) for 30 min
before overnight incubation with BAM10 (Sigma,
A3981, 1/10.000), Iba1 (Wako, VA, USA, /1000), or
GFAP (Dako, Denmark, 1/10000) antibodies at 4 °C.
Sections were rinsed with PBS and then successively
incubated with 1/1000 anti-mouse IgG secondary anti-
body (BA-9200; Vector Labs) at room temperature for
1 h and ABC Vectastain (Vector Labs) before DAB
revelation (DAB SK4100 kit, Vector Labs). Images of
stained sections were digitized with a Zeiss Axio
Scan.Z1 (Zeiss, Jena, Germany) whole slide imaging
microscope at X20 (0.22 μm in plane resolution). The
scanned files were exported as jpeg RGB images with a
30% compression (0.73 μm in plane resolution) using
Zen 2.0 (Zeiss, Jena, Germany). Sections stained for Aβ
were blindly analyzed and Aβ in the hippocampus
quantified using ImageJ software [36]. Segmentation of
β-amyloid deposits was performed in two sections 
corresponding to AP -1.70/− 2.30 mm [27]. It was based 
on the determination of a threshold defined as T = 
Msignal + 10xSDsignal, where  Msignal and SDsignal repre-
sent the mean and standard deviation of the signal 
within a CA1 region of interest in which β-amyloid de-
posits were not visible.
Neuroinflammation was blindly evaluated after manual 
adjustment of a threshold adjusted to select the stained 
microglial and astroglial cells. Their load was quantified 
by densitometry in the inoculated brain region (CA1) 
using Explora Nova Mercator.
Brains sections from tau30+/+ mice were stained with 
anti-AT8 antibodies. Serial sections from the entire brain 
were washed in PBS-0.2% Triton and treated for 30 min 
with H2O2 (0.3%). Non-specific binding was then 
blocked using the MOM kit (Vector MKB2213) (1/100 
in PBS, Vector) for 60 min. Incubation with AT8 
(Thermo Scientific MN1020, 1/500) in PBS-0.2% Triton 
was performed overnight at 4 °C. After several washes, 
labelling was amplified by incubation with an anti-
mouse biotinylated IgG (1/400 in PBS-0.2% Triton, Vec-
tor) for 60 min followed by the application of the ABC 
kit (1:400 in PBS, Vector) prior to visualization with 0.5 
mg/ml DAB (Vector) in 50 mmol/L Tris-HCl, pH 7.6, 
containing 0.075% H2O2. Brain sections were mounted 
onto gelatin-coated slides, stained for 1 min in a cresyl 
violet solution (0.5%), washed in water containing 2%
acetic acid, dehydrated by passage through a graded 
series of alcohol and toluene solutions and mounted 
with Vectamount (Vector) for microscopic analysis. Images 
were digitized with a Zeiss Axio Scan.Z1 (Zeiss, Jena, 
Germany) whole slide imaging microscope at X20 (0.22 μm 
in plane resolution). The density of AT8-positive cell-soma 
profiles in the hippocampus was eval-uated in two sections 
corresponding to AP -1.70/− 2.30 mm [27]. AT8-positive 
cell soma were manually counted (“PointPicker” tool from 
ImageJ [36]) and expressed as the total number of AT8-
positive cell soma profiles vis-ible in the dorsal 
hippocampus.
Stereological counting of NeuN-positive neurons
The optical fractionator method [37, 38] was  used  to  
obtain an unbiased stereological estimate of the total 
number of NeuN-positive cells in the CA1/2 and CA3 
layers of the hippocampus, layers I, II, and III-VI of 
the entorhinal cortex, and the cingulate/retrosplenial 
cortex. Measurements were performed on the left 
hemisphere of the brain. Cells were counted using a 
Leica DM6000 microscope equipped with a digital 
color camera (MicroFireTM, Optronics, Goleta, CA, 
USA), an x-y motorized stage controller, a motorized 
z-axis, and Mercator stereology software (Explora 
Nova, La Rochelle, France). The regions were
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delineated using a 4X objective in accordance with the
mouse lemur brain atlas [31]. Section thickness (from
11 to 13 μm) was measured at three locations for each
section analyzed. Sampling was performed unilaterally
within the delineated areas with a 40X oil-immersion
objective. Counting frames were adapted for each
brain region, and areas of the counting frames (a/f )
were 30 × 30 μm2 to 100 × 100 μm2, depending on the
brain region, while sampling areas were separated by
x-y steps of 50–50 μm to 150–150 μm, depending on
the brain region. The fraction of the section plane
sampled (ASF) was calculated as the ratio (a/f )/(x*y)
(Additional file 1: Table S3). Disector height was
10 μm with a guard zone of 1 μm from the surface of
the section generating counts of 90–2500 sampled
cells per animal, depending on the structure, and the
mean coefficient of error (CE) of the estimates was
0.06 (Additional file 1: Table S3). The total number of
NeuN-positive cells within each region was calculated
according to the following formula: Ntot = ΣQ− × 1/
SSF × 1/ASF × 1/TSF, in which ΣQ− is the number of
sampled cells and SSF is the section sampling fraction.
One out of ten sections was sampled, leaving 200 μm
intervals between two sampled sections. ASF is the
area of the sampling fraction and TSF the thickness of
the sampling fraction. Values of SSF, ASF, and TSF for
each region are given in Additional file 1: Table S3. All
histological data (surface, volume measurements, and
cell counts) were performed by an investigator (SL)
blind to the group assignment of the animals.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software (San Diego, CA, USA). In most graphics, data are
shown as scatter plots with median and interquartile inter-
val. Control-inoculated animals, as well as animals inocu-
lated with each Alzheimer brain homogenates are
displayed with different color codes. Behavioral studies are
not displayed as scatter plots but as mean ± standard devi-
ation (SD) to represent cognition evolution over time.
Cognitive and motor experiments were evaluated by two-
way repeated measures ANOVA (post-inoculation delay,
group) followed by Bonferroni’s multiple comparisons
post-hoc tests. Data normality and variance homogeneity
were evaluated using Shapiro-Wilk and Cochran C tests,
respectively, and data from behavioral experiments were
reciprocally transformed to obtain normality and variance
homogeneity. The values within control-inoculated ani-
mals were highly homogeneous for each post-inoculation
time. We thus replaced missing data for 18 mpi from the
two control-inoculated mouse lemurs that died with the
worst values in the control-inoculated group at 18 mpi.
EEG, neuronal counts and intracellular β-amyloid load in
mouse lemurs, and β-amyloid, tau and inflammation in
mice were evaluated by Mann-Whitney tests. Spearman’s
rank correlations were performed to examine relationships
between EEG and behavioral data. The proportion of
mouse lemurs with β-amyloid lesions in the control- and
Alzheimer-inoculated groups was compared using the
Chi-square test. No statistical methods were used to pre-
determine sample size. Sample size to compare control
and Alzheimer-inoculated mice and mouse lemurs in fu-
ture studies was estimated on the basis of the experimen-
tal results obtained during the current experiments
assuming a significance level of 5%, a power of 80% and
two-sided tests. Estimations for quantitative values used a
two-sample t-test on the basis of the mean and standard
deviation obtained for the different measures in this study
(BiostaTGV module, https://biostatgv.sentiweb.fr/?mod-
ule=etudes/sujets#). The standard deviation used for this
estimation was the square root of the pooled variance
from each group. Estimations for proportional values
(proportion of lemurs with Aβ, CAA or Tau in the brain)
were based on a chi-squared test (BiostaTGV module
based on epiR package 0.9–9.6, https://biostatgv.sentiweb.
fr/?module=etudes/sujets#).
Results
Characterization of human brain samples and
homogenates
Frozen brain tissue samples (parietal cortex) from two
Alzheimer’s disease patients (Braak and Braak stage VI,
Thal stages 5 and 4, respectively) and one control individ-
ual (Braak and Braak/Thal stages 0) were used in the
current study. The brains of the Alzheimer’s disease pa-
tients displayed typical lesions (β-amyloid plaques and tau
tangles) while no lesions were found in the control subject
(Additional file 3: Figure S2a-h). One Alzheimer case
(AD1) displayed β-amyloid angiopathy in addition to β-
amyloid plaques while the second Alzheimer patient
(AD2) did not display angiopathy (Additional file 3: Figure
S2a-d). Immunohistochemical staining for alpha-synuclein
was negative for all brain samples. Biochemical analysis
revealed high Aβ1–42 and Aβ1–40 levels only in Alzheimer’s
disease-brain homogenates (Additional file 3: Figure S2i-
j). AD1 displayed higher Aβ1–40 and lower Aβ1–42 levels
than AD2 (Additional file 3: Figure S2i-j). Western blot-
ting showed a typical shift in the molecular weight of the
Alzheimer tau-Cter triplet [23] and the presence of patho-
logical pS396 tau only in Alzheimer samples (Additional
file 3: Figure S2k-l). All brain samples were negative for
presence of Prion proteins assessed by western blotting
(Additional file 4: Figure S3).
Alzheimer’s disease brain inoculation effectively induces
β-amyloid and tau lesions in transgenic mice
Prior to being used in mouse lemurs, the Alzheimer’s
disease and control brains were inoculated in the
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hippocampus of APP/PS1dE9 and Tau30
+/+ mouse
models of β-amyloid and tau lesions. Alzheimer’s disease
brain homogenates led to increased Aβ and tau
deposition in APP/PS1dE9 and Tau30
+/+ mice (p = 0.009
and p = 0.0007, respectively, Additional file 5: Figure
S4a-f ). Within the Alzheimer group, the β-amyloid load
was higher in the mice inoculated with the brain pre-
senting with β-amyloid angiopathy as compared to the
mice inoculated with the brain without angiopathy (p =
0.01). No difference was detected for tau lesions. This
experiment confirmed the ability of the Alzheimer’s dis-
ease brain homogenates to induce transmission of Alz-
heimer’s disease-related lesions in mice.
Alzheimer’s disease brain inoculation induces cognitive
alterations in mouse lemurs
Following the mouse studies, 12 adult mouse lemurs
were inoculated with the same Alzheimer’s disease
and control human brain homogenates. Motor func-
tions, assessed with a rotarod test were similar in
both groups (Fig. 1a). Cognitive evaluation was per-
formed every 6 months in a jumping-stand apparatus
[28] (Additional file 2: Figure S1a) and consisted of
two tasks (Additional file 2: Figure S1b). The first
was a learning task that rated visual discrimination
acquisition abilities, whereas the second was a long-
term memory task that assessed retention of the dis-
crimination problem learned 6 months before. Before
brain homogenate inoculation, animals assigned to
Alzheimer- and control-inoculated groups performed
similarly in the learning task (Fig. 1b). Animals from
both groups showed similar improvement in their
learning abilities 6 months after inoculation (Fig. 1b).
However, performance then diverged with control-
inoculated animals further improving at 12 mpi, until
reaching the best possible scores (thus demonstrating
learning set acquisition), whereas the Alzheimer-
inoculated group progressively worsened at both 12
and 18 mpi, with overall performance significantly
Fig. 1 Cognitive dysfunction in Alzheimer-inoculated mouse lemurs.
a The rotarod test did not reveal any motor dysfunction in either
Alzheimer- (AD) or control- (CTRL) inoculated group. b Progressive
learning impairment in the animals of the Alzheimer-inoculated
group. Animals allocated to Alzheimer- and control- inoculated
groups performed similarly before inoculation and improved
similarly up to 6 mpi. Only the control-inoculated group continued
to improve at 12 and 18 mpi (p < 0.0001 and p = 0.01, respectively).
Learning abilities were also lower in the Alzheimer-inoculated group
than in the control-inoculated group at 12 mpi (p = 0.03) and
tended to be lower at 18 mpi (p = 0.10). The overall performance of
the Alzheimer-inoculated group was significantly worse than that of
the control-inoculated group (p = 0.02). c The overall performance of
the Alzheimer-inoculated group in the long-term memory task at 6
and 18 mpi was significantly worse than that of control animals (p =
0.0002, 0.0036, and 0.0024, respectively). *p < 0.05; **p < 0.01; ***p <
0.001 (n = 6 per group, two-way repeated measures ANOVA with
Bonferroni’s post-hoc tests). Plots presents mean ± standard
deviation. Dashed lines in (b, c) indicate the best possible scores
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lower than that of control-inoculated group (Fig. 1c).
The overall performance of the Alzheimer-inoculated
group in the long-term memory task and their per-
formance at 6 and 18 mpi were significantly worse
than those of control-inoculated group (Fig. 1c). We
did not detect any difference between the scores ob-
tained by the animals inoculated with tissue homoge-
nates from the two Alzheimer brains.
Alzheimer’s disease brain inoculation alter EEG measures
Longitudinal EEG studies were performed in mouse le-
murs in order to further evaluate neuronal activity in the
Alzheimer- and control-inoculated groups. EEG measures
were recorded in the frontal cortex during the active state
before the inoculation (Fig. 2a). At 6 mpi, slow wave EEG
frequencies were altered, with a lower delta frequency and
a higher theta frequency in the Alzheimer- than in the
control-inoculated group (Fig. 2b). In addition, the de-
crease in delta frequency correlated significantly with im-
pairment of long-term memory (p = 0.009, Additional file
6: Figure S5). Lemurs from the Alzheimer-inoculated
group still displayed a significantly lower delta frequency
and a significantly higher fast wave (alpha, sigma, and
beta) frequency (Fig. 2c) at 12 mpi than lemurs from the
control-inoculated group. We did not detect any
difference between the scores obtained by the animals in-
oculated with tissue homogenates from the two Alzheimer
brains.
Alzheimer’s disease brain inoculation induces a
progressive cerebral atrophy
Alzheimer’s disease is morphologically characterized
by progressive cerebral atrophy affecting the hippo-
campus and the cortex. We recorded MR images of
the brains of lemurs from Alzheimer- and control-
inoculated groups every 3 months. Automated voxel-
based analysis was performed to evaluate cerebral
atrophy. The Alzheimer-inoculated group displayed
strong bilateral atrophy of the retrosplenial and pos-
terior cingulate cortices (two areas close to the
inoculation sites) relative to the control-inoculated
group (Fig. 3a-c, dark blue clusters in b-c; Additional
file 1: Table S4). Atrophy also involved temporal
Fig. 2 Neuronal activity alterations in Alzheimer-inoculated mouse
lemurs. Evolution of EEG frequency power densities in the
Alzheimer- (AD) and control- (CTRL) inoculated groups before
inoculation (a), and 6 (b) and 12 (c) mpi (n = 6 per group). a EEG
frequency power densities were similar in the two groups before
inoculation. b At 6 mpi, the Alzheimer-inoculated group showed a
lower delta frequency (0.5–4 Hz) and a higher theta frequency (4–8
Hz) than the control-inoculated group (p = 0.009 and p = 0.002,
respectively, Mann-Whitney tests). c At 12 mpi, the alterations in
delta frequency were maintained (p = 0.009, Mann-Whitney test). In
addition, alpha (8–12 Hz), sigma (12–16 Hz), and beta (16–24 Hz)
frequencies were higher in the Alzheimer-inoculated group than in
the control-inoculated group (p = 0.004, p = 0.015, and p = 0.009,
respectively, Mann-Whitney tests). *p < 0.05; **p < 0.01. Scatter plots
display median and interquartile interval. CTRL-inoculated animals
are in blue, AD1-inoculated in green and AD2-inoculated in red
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regions, including the hippocampus, entorhinal cortex,
amygdala, and inferior temporal cortex (Fig. 3a-c,
light blue clusters in b-c) with greater atrophy in the
left hemisphere as compared to the right hemisphere.
We also detected atrophy in the diagonal band of
Broca, fornix, stria terminalis, parietal cortex, and
caudate nucleus (Fig. 3a-c, gray clusters in b-c; Add-
itional file 1: Table S4). Follow-up of the atrophied
regions showed that the process was mild at 6 mpi
and mainly developed from 6 to 12 mpi. Thus, atro-
phy was not associated with an acute effect of the in-
oculation and continued to spread from 12 to 18
mpi, although to a lesser extent (Additional file 7:
Figure S6).
Alzheimer’s disease brain inoculation induces neuronal
loss
Mouse lemurs were euthanized at 18 mpi, at 5.0 ± 0.2
years of age. Serial sections of the entire brains were
stained with NeuN antibody and neurons counted in
the hippocampus, entorhinal and cingulate/retrosple-
nial (RS) cortices by unbiased stereology (Fig. 4a-c).
There was significant neuronal loss in the CA3 pyr-
amidal layer of the hippocampus (p = 0.02) and in
layers II (p = 0.03) and III to VI (III-VI, p = 0.03) of
the entorhinal cortex (Fig. 4d-f ). Neuronal counts in
these three structures positively correlated with each
other (all p < 0.02). Neuronal counts in the CA1/2 re-
gion of the hippocampus, layer I of the entorhinal
Fig. 3 Cerebral atrophy in Alzheimer-inoculated compared to control-inoculated mouse lemurs. a Statistical parametric maps depicting regions in
which cerebral tissue volume decreased in the Alzheimer-inoculated group compared to the control group. The color-coded blobs show
statistical differences between Alzheimer-inoculated animals and control-inoculated mouse lemurs. Images follow the radiological convention (i.e.
left hemisphere is on the left). Slices are spaced 0.5 mm apart along the rostro-caudal axis (voxel-based morphometric parameters: FDR-corrected
p < 0.05; extent threshold k = 10; map represents t values). Lateral b and (c) dorsal 3D representations of atrophied areas. Orientation of the brain
is explained by the crossing arrows, and letters. A: anterior; P: posterior; D: dorsal; V: ventral; L: left; R: right; EC: entorhinal cortex; DB: diagonal
band of Broca; Am: amygdala; Hip: hippocampus; nST: nucleus stria terminalis; Fx: fornix; Cd: caudate nucleus; Pva: peri-third ventricle area; IT:
inferotemporal cortex; PC: posterior cingulate cortex; RS: retrosplenial cortex. Orange arrow and crosses represent the injection coordinates. Dark
blue clusters represent voxels with significant atrophy in the posterior cingulate and retrosplenial cortex. Light blue clusters represent voxels with
significant tissue atrophy in the temporal areas of the brain (including the hippocampus, entorhinal cortex, amygdala, and lateral and inferior
temporal cortices) as well as the diagonal band of Broca, fornix, and nucleus stria terminalis. Gray clusters represent other significant voxels. Maps
derived from MRI recorded on n = 6 animals per group at 0, 3, 6, and 9 mpi and n = 6 and 4 animals in the Alzheimer- and control-inoculated
groups, respectively, at 12, 15, and 18 mpi
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cortex, and cingulate/retrosplenial cortex were not
significantly affected by inoculation with Alzheimer’s
disease brain homogenates (Fig. 4g-i). We did not de-
tect any difference in neuronal counts in the animals
inoculated with tissue homogenates from the two
Alzheimer brains.
Alzheimer’s disease brain inoculation induces β-amyloid
and tau lesions
We then evaluated mouse lemur brain sections for Aβ and
tau pathologies (Table 1). In two out of five Alzheimer-
inoculated mouse lemurs Aβ and tau deposits were de-
tected close to the inoculation sites (Figs. 5 and 6). In the
three other Alzheimer-inoculated animals Aβ deposits were
also detected, but tau was not detected. Neither type of
deposit was detected in the control-inoculated animals. β-
amyloid deposits were found as β-amyloid plaques (Figs.
5a-b, 6) as well as bands of parenchymal β-amyloid deposits
surrounding white matter tracts (Figs. 5f-g and 6) in
animals inoculated with tissue homogenates from the two
Alzheimer brains (AD1 and AD2). β-amyloid angiopathy
was detected only in one animal inoculated with the tissue
homogenate from the Alzheimer brain displaying β-
amyloid angiopathy (Fig. 5c-e). Tau lesions were detected
using different antibodies including AT8, MC1 and AT100
(Fig. 5h-q), and were mainly in the form of neuropil threads
Fig. 4 Neuronal loss in Alzheimer-inoculated mouse lemurs. NeuN staining of the dorsal hippocampus in animals of the (a) control- (CTRL) and
(b) Alzheimer-inoculated (AD) groups. CA1/2 and CA3 are highlighted. c Stereological counting revealed a reduction in the number of NeuN-
positive neurons in the CA3. NeuN staining of the entorhinal cortex (EC) in control- (d) and Alzheimer-inoculated (e) groups. EC-I, EC-II, and EC-III-
VI represent the different layers of the entorhinal cortex. f Stereological counting revealed a reduction in the number of NeuN-positive neurons in
layers II and III-VI of the EC. NeuN staining of the cingulate/retrosplenial cortex (Cg/RS) in control- (g) and Alzheimer-inoculated (h) groups. i
Stereological counting did not reveal changes of NeuN-positive neurons in the Cg/RS. Scale bars: 100 μm. *p < 0.05, Mann-Whitney test. Scatter
plots display median and interquartile interval. CTRL-inoculated animals are in blue, AD1-inoculated in green and AD2-inoculated in red
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(Fig. 5j-n). Intracellular tau positive structures were also
detected in the form of globular tau positive cells, horse-
shoe and punctiform tau accumulation (Fig. 5o). We also
found rare somatodentridic inclusions (Fig. 5k, p) as well
as immunoreactive neurites with varicosities or “strings of
beads” labeling (Fig. 5k), a pattern that is considered indi-
cative of early changes in the process of tau-related neuro-
fibrillary degeneration [39, 40]. Tau lesions were not
colocalized with oligodendrocytes (Fig. 5q), but they were
always seen in regions in which β-amyloid could be
detected (Fig. 5h-i and 6). The two animals displaying tau
lesions were inoculated with different Alzheimer brain
samples (one animal inoculated with AD1 and one animal
inoculated with AD2). To further evaluate the impact of
the induced tau pathology on the clinical/neuropatho-
logical outcomes, we split the Alzheimer-inoculated ani-
mals into two subgroups of tau-positive and tau-negative
animals (Additional file 8: Figure S7). The two animals
displaying tau lesions had the worst memory scores at 18
mpi as well as the lowest neuronal counts in the CA3 re-
gion of the hippocampus.
Interestingly, β-amyloid depositions and tau inclusions
could be visualized in several coronal brain sections
encompassing the injection sites and the levels up to 1
mm anterior and 1mm posterior to the injection site,
and up to ~ 2mm away from the injection site in the
section plane, suggesting the spreading of the lesion
(Figs. 5 and 6).
We also focused on 4G8-positive intracellular
staining that reflects APP/Aβ deposition in mouse
lemurs [18, 19]. Intracellular staining was measured
in both groups (Additional file 9: Figure S8), but
there were no statistically significant differences be-
tween Alzheimer- and control-inoculated groups ei-
ther in particular structures like the hippocampus
(Additional file 9: Figure S8d), the caudate and puta-
men (not shown) or in the whole brain (Additional
file 9: Figure S8h).
We did not detect obvious signs of astrocytic reactivity in
any mouse lemur (Fig. 7a-b, e), and the evaluation of
microglial reactivity did not reveal any difference between
the Alzheimer- and control-inoculated groups (Fig. 7c-d, f).
These results are consistent with the lack of differences in
inflammation detected in APP/PS1dE9 mice between both
groups (Additional file 5: Figure S4g-j).
Discussion
This study demonstrated that inoculation of Alzheimer’s
disease brain homogenates in middle-aged mouse lemurs
induces alterations of long term memory and progressive
loss of learning ability, modifications of neuronal activity
detected by EEG, widespread and progressive cerebral at-
rophy, and neuronal loss in the hippocampus and entorhi-
nal cortex. The Alzheimer’s disease brain homogenates
that induced these alterations accelerated the occurrence
of β-amyloid and tau lesions in transgenic mouse models
of β-amyloid or tau. This result in mice is consistent with
the literature [7, 8]. β-amyloid and tau lesions were also
induced in mouse lemurs by inoculation with Alzheimer’s
disease brain homogenates but not with the control brain
homogenates. These lesions were localized close to the in-
oculation sites, which supports the role of the Alzheimer’s
disease brain homogenates in inducing them. This is the
first direct evidence of transmission of both β-amyloid
and tau lesions in a non-transgenic animal. Interestingly,
the lesions observed in mouse lemurs were sparse while
they were more severe in transgenic mice. Thus, experi-
mental transmission using the same Alzheimer’s disease
brain homogenates leads to differential effects in different
species.
Alzheimer’s disease is characterized by the pres-
ence of substantial amount of β-amyloid plaques [41,
42] in association with tau pathology [3]. In humans,
the absence of these lesions precludes the diagnosis
of Alzheimer’s disease. Brains of Alzheimer patients
are also characterized by neuronal loss that exceeds
tau pathology [2] and cerebral atrophy. Studies of
the impact of experimental inoculation of Alzheimer
brain homogenates in mice usually focus only on β-
amyloid and tau lesions, but do not reveal conse-
quences of inoculations on clinical signs, neuronal
alterations or cerebral atrophy, despite the import-
ance of these signs for Alzheimer’s disease. In the
mouse lemurs of this study while the sparsity of the
induced amyloid and tau lesions do not directly sup-
port a diagnosis for an “Alzheimer-like” pathology,
Table 1 β-amyloid and tau lesions in mouse lemurs of the
Alzheimer- (AD) and control-inoculated (CTRL) groups. β-
amyloid plaques or β-amyloid angiopathy (CAA) were detected
only in Alzheimer-inoculated animals. Tau lesions detected in
two Alzheimer-inoculated animals (AT8, MC1 and AT100
antibodies). * correspond to two animals that were euthanized
at 12 months post inoculation. AD1 displayed β-amyloid
angiopathy, high Aβ1–40 and low Aβ1–42 levels. AD2 did not
display angiopathy and had low Aβ1–40 and high Aβ1–42 levels
Group Animal β-Amyloid Tau - AT8 Tau - MC1 Tau - AT100
AD2 265B + (plaques) ++ ++ ++
AD2 260B + (plaques) ++ ++ ++
AD1 169ABC ± (plaques) 0 0 0
AD2 190IAB ± (plaques) 0 0 0
AD1 211DBA ± (CAA) 0 0 0
CTRL 189CBD 0 0 0 0
CTRL 190IC 0 0 0 0
CTRL 169ABB 0 0 0 0
CTRL 259BB* 0 0 0 0
CTRL 213ABA* 0 0 0 0
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the encephalopathy developed by the inoculated le-
murs is clinically relevant as it was associated with
cognitive alterations, widespread cerebral atrophy,
modifications of neuronal activity, and neuronal loss.
Further, this encephalopathy is likely related to
Alzheimer pathology as it was induced by inocula-
tion of Alzheimer brain homogenates (and not con-
trol homogenates) and because the inoculated
animals presented with β-amyloid and tau lesions
even if they were sparse.
Fig. 5 (See legend on next page.)
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The neuronal loss reported in the mouse lemurs inocu-
lated with Alzheimer’s disease brain homogenates involved
the CA3 region of the hippocampus as well as the layers II
and III to VI of the entorhinal cortex. These alterations are
consistent with the macroscopic atrophy detected in the
hippocampus and entorhinal cortex by MRI. The
Alzheimer-inoculated animals also displayed a macroscopic
atrophy of the retrosplenial and posterior cingulate cortices.
The CA3 region is connected with layers II and III of the
entorhinal cortex by the perforant path [43], and layer II of
the entorhinal cortex is connected to the retrosplenial and
the posterior cingulate cortices [44]. Thus, the atrophy oc-
curred within an organized network rather than randomly
in the brain. This network connecting CA3, layer II of the
entorhinal, retrosplenial and posterior cingulate cortices is
strongly involved in memory for contextual information
that is important for the long-term retention of a simple
visual discrimination task [45, 46]. Its alteration in
Alzheimer-inoculated mouse lemurs is thus consistent with
their memory impairments. In addition to the neuronal
loss, we found progressive impairments of neuronal activity
detected first at a lower delta frequency and then at a
(See figure on previous page.)
Fig. 5 Amyloid depositions and tau inclusions in Alzheimer-inoculated mouse lemurs. a, b β-amyloid plaques (insets, arrows) revealed in two
brain sections, immunostained for Aβ (4G8), separated from 1 mm in an animal from the Alzheimer-inoculated group. The inoculation site is
shown with an open arrow (b). β-amyloid could also be detected in blood vessels (c-e) as well as in the parenchyma (f-g) close to the corpus
callosum (arrows, images in f-g correspond to frames in a-b). Immunostaining for tau lesions using AT8 (h, j, k, o), MC1 (l) and AT100 (i, m-n, p).
h-i frames display the same regions as the ones shown in (f-g): tau lesions (arrows) were detected in the same regions as Aβ. j-n are magnified
images showing tau in neuropil threads (arrows). Intracellular tau positive structures were also detected in the form of globular positive cells
(arrow), horseshoe intracellular accumulation (dotted arrow) and punctiform intracellular accumulation (arrowhead) (o). Rare somatodentridic
inclusions (arrowhead k, p) as well as immunoreactive neurites with varicosities or "strings of beads" labeling (k: dotted arrow) were also
detected. Tau stainings were counterstained with cresyl violet to identify neurons in (h-p). q displays AT8 sections double-stained for
oligodendrocytes. Tau-positive lesions were not colocalized with oligodendrocytes (AT8 (brown) and Olig2 (red)). Scale bars: 1 mm (a-b), 200 μm
(insets in a-b, e-i), 50 μm (c-e, j-m, q), 10μm (n-p)
Fig. 6 Diffusion of β-amyloid deposits and tau inclusions in Alzheimer-inoculated mouse lemurs. Immunostaining of Aβ (4G8, a-e, k-o (magnified
views)) and tau (AT8, f-j, p-y (magnified views)) in 5 successive brain sections. u-y displays magnification of the tau-positive lesions from (f-j) or
(p-t). β-amyloid and tau deposits (a-t) were seen exactly at the same locations (arrows). They spread from the inoculation site (open arrow in b,
c) to regions localized one millimeter ahead and behind the inoculation site (A1.50 mm to P0.50 mm correspond to spatial references in the Bons
atlas [31]). Scale bars: 1 mm (a-j), 200 μm (k-t), 50 μm (u-y)
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higher theta frequency in EEG measures. This suggests a
long-distance functional impact of the pathological brain
homogenate on neuronal network activity.
Mouse lemurs were euthanized 18months after inocula-
tion of brain homogenates as they displayed clinical signs
including cognitive alterations, modifications of neuronal
activity detected by EEG, and cerebral atrophy. The lack
of severe β-amyloidosis, tau lesions or neuroinflammation
in their brains despite their clinical signs is intriguing. β-
amyloid and tau lesions were detected 4 and 1 mpi in
mouse models of amyloidosis and tauopathy, respectively.
Thus the Alzheimer brain homogenates that we used are
able to induce β-amyloid and tau lesions relatively quickly
in mice. We made the choice to follow up the mouse le-
murs up to 18months after inoculation, where they reach
around 5 years and are considered as middle-aged, in
order to avoid age-related cognitive or neuropathological
impairments. Thus, we cannot rule out the possibility that
they would have developed stronger neuropathological le-
sions if they had lived longer. Indeed, β-amyloid and/or
tau accumulation in non-human primates has been re-
ported to take many years [11]. However, since in humans
with Alzheimer’s disease the amyloid or tau lesions occur
before cognitive alterations, cerebral atrophy or neuronal
loss [47], we expected to detect stronger β-amyloid and/or
tau lesions in lemurs that displayed clinical signs. These
expectations were based on the facts that primates: i. nat-
urally express β-amyloid or tau under normal conditions;
ii. are genetically more similar to humans than transgenic
mouse models of Alzheimer’s disease [48]; and iii. Can
naturally display age-related cerebral atrophy associated
with cognitive changes [16], all resulting in primates being
relevant models to explore impact of experimental inocu-
lation of Alzheimer brain homogenates that cannot be
evaluated in mouse models. With this in mind, one inter-
pretation of the observed presence of encephalopathy not
Fig. 7 Lack of glial reactivity in inoculated lemurs. a-b, Immunostaining of astrocytes (GFAP) in the hippocampus (H) and parietal cortex (P) of
control (a) and Alzheimer-inoculated (b) animals. Regional differences are seen including lower GFAP-immunoreactivity in the cortices which is
generally found in lemurs. No qualitative difference in astrocyte morphology was detected between control- and Alzheimer-inoculated animals.
Scale bars: main frame: 1 mm; inserts: 50 μm. (c) Quantitative evaluations of astrocyte reactivity did not provide evidence of changes in GFAP-
immunoreactivity or astrocyte morphology between control- and Alzheimer-inoculated animals (Mann-Whitney tests). d-f Microglia reactivity was
evaluated by western blot analysis (Iba1). The unstained -UV activated- blot used for total protein amount normalization is presented in (d), while
the blot probed with Iba-1 antibody showing a specific 16kD band is displayed in (e). f Quantitative evaluations of the blots did not show any
difference between Iba-1 expression in control- and Alzheimer-inoculated animals (Mann-Whitney test). Scatter plots display median and
interquartile interval. CTRL-inoculated animals are in blue, AD1-inoculated in green and AD2-inoculated in red. N = 6 animals per group. FC:
frontal cortex; EC: entorhinal cortex; Am: amygdala; Hip: hippocampus; Cg/RS: cingulate cortex/retrosplenial cortex
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associated with a strong inflammatory process, β-amyloid
or tau deposition following Alzheimer brain homogenate
intracerebral inoculation lies in research on prion diseases.
Indeed, the induction of clinical signs and neuronal death
in the absence of detectable pathological protein accumu-
lation after inoculation of brain homogenates was previ-
ously reported for classical prion diseases [49]. In prion
diseases, this is explained by the presence of soluble
agents that are thought to be neurotoxic [50]. Further, as
soluble, oligomeric, forms of β-amyloid [51] and tau [52]
are known to be toxic for the brain, one possible explan-
ation for our results is that inoculation of human Alzhei-
mer brain homogenates led to the production of such
oligomers that were toxic for neurons. The two animals
presenting with aggregated tau lesions had the worst mem-
ory scores and the lowest neuronal density in CA3. Given
the low density of these tau lesions, we rule out that they
directly induced neuronal loss. However, they could be as-
sociated with soluble forms of tau, an entity that induces
more neuronal loss than aggregated tau proteins [53]. One
can however not exclude the influence of other as yet un-
identified factors leading to the reported encephalopathy.
Although the evidence for cognitive and patho-
logical alterations in Alzheimer’s brain-inoculated
middle-aged animals emphasizes our findings, one
limitation of the current study is that it was de-
signed to focus on neuropathological alterations and
brains were perfused with paraformaldehyde, which
limited our ability to perform biochemical analysis.
Future studies should include more in-depth examin-
ation of biochemical changes following Alzheimer
brain inoculation. Thioflavin-T binding affinity
should be used to assess the fibrillary nature of the
β-amyloid and tau compounds present in animal
brains [54]. β-amyloid and tau oligomers should then
be evaluated by mass spectrometry [55], RT-QuiC
analysis [55], immunoprecipitation experiments, and
fast protein liquid chromatography [54]. Atomic
force microscopy as well as a newly developed
ELISA-like technique called sFIDA (Surface-Based
Fluorescence Intensity Distribution Analysis Assay)
should also be used to further describe the oligomers
and their size [54, 56].
Another potential limitation of the study may be the
small size of the animal groups that can be reached while
working with primates. Using results from our studies
(mean/standard deviation obtained for the different
measures, proportion of animals displaying with amyloid or
tau pathologies in our experimental groups) we could esti-
mate the sample size to compare groups of control- and
Alzheimer-inoculated animals assuming a significance level
of 5%, a power of 80%, and two-sided tests (Additional file
1: Table S5, [57]). In mouse lemurs, small number of ani-
mals (n < 5) per arm are required to detect memory
alterations or EEG changes after 6 mpi as well as cerebral
Aβ deposition at 18 mpi. Detection of neuronal loss in the
CA3 as well as in layers II and III to VI of the entorhinal
cortex requires from 5 to 8 animals. These values should be
compared to estimations of sample sizes in mice that re-
quire from 1 to 8 mice to assess tau or amyloid deposition.
They show that the number of mouse lemurs required to
obtain scientific results is in the same range as the one re-
quired for transgenic rodents. Mouse lemurs however pro-
vide new types of information as they can spontaneously
display amyloid or tau lesions on a wild-type/primate gen-
etic background as well as neuronal loss associated to clin-
ical outcomes. They can be ideal models to assess the
impact of various amyloid/tau strains on disease occurrence
or the role of oligomers on clinical outcomes in primates.
In conclusion, our results indicate that Alzheimer’s dis-
ease brain homogenate inoculation induces an encephalop-
athy characterized by neuronal loss, progressive atrophy,
neuronal activity alterations and cognitive impairments as
well as sparse β-amyloid and tau depositions. The clinical
signs can be explained by the neuronal loss, cerebral atro-
phy and neuronal networks dysfunction. Tau lesions may
be a strong determinant, but not the only one, in the induc-
tion of the neuronal loss and clinical outcome. Further
studies are necessary to evaluate the nature of relationships
between the different lesions induced by Alzheimer’s dis-
ease brain homogenate inoculation and to assess the mech-
anisms leading to encephalopathy induced by these
inoculations.
Additional files
Additional file 1: Table S1 Human brain sample characteristics and
staging. Table S2 Schedule of the experimental protocol. Table S3
Sampling parameters for stereological counting of NeuN-positive neu-
rons. Table S4 Brain regions with gray matter loss in the Alzheimer's
disease-inoculated group relative to the control-inoculated group. Table
S5 Estimated sample size to compare control and Alzheimer-inoculated
mice and mouse lemurs assuming a significance level of 5%, a power of
80%, and two-sided tests. (DOCX 46 kb)
Additional file 2: Figure S1 Cognitive test in mouse lemurs. (TIF 5572
kb)
Additional file 3: Figure S2 Characterization of human brain samples
and homogenates. (TIF 19464 kb)
Additional file 4: Figure S3 Prion protein examination in human brain
samples. (TIF 9854 kb)
Additional file 5: Figure S4 Aβ and Tau pathology in mice after
inoculation with human brain homogenates. (TIF 26552 kb)
Additional file 6: Figure S5 Correlation between cognitive abilities and
EEG delta frequency. (TIF 4153 kb)
Additional file 7: Figure S6 Time-dependent evolution of cerebral atro-
phy in inoculated lemurs. (TIF 19870 kb)
Additional file 8: Figure S7 Impact of tau pathology on memory and
neuronal loss. (TIF 8800 kb)
Additional file 9: Figure S8 Similar level of intracellular 4G8-positive
structures in Alzheimer’s disease and control-inoculated lemurs. (TIF
21279 kb)
Gary et al. Acta Neuropathologica Communications           (2019) 7:126 Page 18 of 21
Acknowledgements
We thank V. Buee-Scherrer for biochemical evaluation of tau. We also thank the
donors and the Brain Donation Program of the “GIE NeuroCEB” Brain Bank run by
a consortium of Patient Associations: ARSEP (association for research on multiple
sclerosis), CSC (cerebellar ataxias), France Alzheimer and France Parkinson, with the
support of Fondation Plan Alzheimer and IHU A-ICM for providing the brain
samples used in this study.
GIE Neuro-CEB: Charles Duyckaerts, Véronique Sazdovitch, Sabrina Leclère-Turbant,
and Marie-Claire Artaud-Botté; The national network includes the following
neuropathologists: Anne Vital (Bordeaux), Françoise Chapon (Caen), Jean-Louis
Kemeny (Clermont-Ferrand), Claude-Alain Maurage & Vincent Deramecourt (Lille),
David Meyronet & Nathalie Streichenberger (Lyon), André Maues de Paula
(Marseille), Valérie Rigau (Montpellier), Fanny Vandenbos-Burel (Nice), Charles
Duyckaerts (Paris), Danielle Seilhean (Paris), Véronique Sazdovitch (Paris), Serge
Milin (Poitiers), Dan Christian Chiforeanu (Rennes), Annie Laquerrière (Rouen),
Béatrice Lannes (Strasbourg), Marie-Bernadette Delisle & Emmanuelle Uro-Coste
(Toulouse).
Authors’ contributions
CG, JK, EEC, JLP, FPi, and MD designed the study. MD coordinated the study.
FNN provided the human brain samples. LB, SE, FNN, ASH, and CG
characterized the brain samples. CG, MD, and JK performed the inoculations
and the MRI study. CG, SJS, JLP, and MD, designed the MRI analysis. FA and
FPi raised the mouse lemurs and conducted the EEG evaluations. JLP
performed cognitive evaluation. FPi performed rotarod test. FPe, PG, ASH
and CG performed the immunohistological studies of the mouse lemur
brains. SL performed the stereology of the mouse lemur brains. CG and SL
conducted the experiments and measurements in APP/PS1dE9 mice. RC, MC
and LB performed the experiments in Tau30+/+ mice. CG, ASH and MD
were responsible for statistical analysis and wrote the manuscript. JK, LB, CD,
ASH, JPD, EEC, JLP, and FPi revised the manuscript. All authors read and
approved the final manuscript.
Funding
This study was funded by the France-Alzheimer Association, the Fondation
Plan Alzheimer, and the CEA Bottom-Up program.
Availability of data and materials
The datasets during and/or analysed during the current study available from
the corresponding author on reasonable request.
Competing interests
The authors declare that they have no competing interests.
Author details
1Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud,
Université Paris-Saclay UMR 9199, Laboratoire des Maladies
Neurodégénératives, 18 Route du Panorama, F-92265 Fontenay-aux-Roses,
France. 2Commissariat à l’Energie Atomique et aux Energies Alternatives
(CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob,
MIRCen, 18 Route du Panorama, F-92265 Fontenay-aux-Roses, France.
3University of Wisconsin Oshkosh, 800 Algoma Boulevard, Oshkosh, WI
54901, USA. 4Wolfson Brain Imaging Centre, University of Cambridge,
Addenbrooke’s Hospital, Cambridge Biomedical Campus, Cambridge CB2
0QQ, UK. 5Behavioural and Clinical Neuroscience Institute, University of
Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. 6LabEx
DISTALZ (Development of Innovative Strategies for a Transdisciplinary
approach to ALZheimer’s disease), Université de Lille, Inserm, CHU-Lille,
UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France.
7UMR7179 CNRS-MNHN, MECADEV (Adaptive Mechanisms and Evolution), 1
Avenue du Petit Château, 91800 Brunoy, France. 8Commissariat à l’Energie
Atomique et aux Energies Alternatives (CEA), Direction de la Recherche
Fondamentale (DRF), Institut François Jacob, SEPIA, Université Paris-Saclay, 18
Route du Panorama, F-92265 Fontenay-aux-Roses, France. 9GIE Neuro-CEB/
Neuropathologist Network: Plate-Forme de Ressources Biologiques, Bâtiment
Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 Boulevard de l’Hôpital,
Cedex 13, 75651 Paris, France. 10Laboratoire de Psychopathologie et de
Neuropsychologie, EA, 2027, Université Paris 8, St-Denis, France.
Received: 15 July 2019 Accepted: 15 July 2019
References
1. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical
use of structural MRI in Alzheimer disease. Nat Rev Neurol 6:67–77. https://
doi.org/10.1038/nrneurol.2009.215
2. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE,
Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary
tangles in Alzheimer's disease. Ann Neurol 41:17–24. https://doi.org/10.1
002/ana.410410106
3. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic
pathology of Alzheimer disease. Acta Neuropathol 118:5–36. https://doi.
org/10.1007/s00401-009-0532-1
4. Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J,
Launchbury F, Linehan J, Richard-Loendt A, Walker AS, Rudge P, Collinge J,
Brandner S (2015) Evidence for human transmission of amyloid-beta
pathology and cerebral amyloid angiopathy. Nature 525:247–250. https://
doi.org/10.1038/nature15369
5. Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, Koriath
C, Sciot R, Mead S, Brandner S (2018) Evidence of amyloid-beta cerebral
amyloid angiopathy transmission through neurosurgery. Acta Neuropathol
135:671–679. https://doi.org/10.1007/s00401-018-1822-2
6. Kovacs GG, Lutz MI, Ricken G, Strobel T, Hoftberger R, Preusser M,
Regelsberger G, Honigschnabl S, Reiner A, Fischer P, Budka H, Hainfellner JA
(2016) Dura mater is a potential source of Abeta seeds. Acta Neuropathol
131:911–923. https://doi.org/10.1007/s00401-016-1565-x
7. Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M,
Tolnay M (2014) Peripheral administration of tau aggregates triggers
intracerebral tauopathy in transgenic mice. Acta Neuropathol 127:299–301.
https://doi.org/10.1007/s00401-013-1231-5
8. Eisele YS, Fritschi SK, Hamaguchi T, Obermuller U, Fuger P, Skodras A,
Schafer C, Odenthal J, Heikenwalder M, Staufenbiel M, Jucker M (2014)
Multiple factors contribute to the peripheral induction of cerebral beta-
amyloidosis. J Neurosci 34:10264–10273. https://doi.org/10.1523/
JNEUROSCI.1608-14.2014
9. Beekes M, Thomzig A, Schulz-Schaeffer WJ, Burger R (2014) Is there a risk of
prion-like disease transmission by Alzheimer- or Parkinson-associated
protein particles? Acta Neuropathol 128:463–476. https://doi.org/10.1007/
s00401-014-1324-9
10. Heuer E, Rosen RF, Cintron A, Walker LC (2012) Nonhuman primate models
of Alzheimer-like cerebral proteopathy. Curr Pharm Des 18:1159–1169.
https://doi.org/10.2174/138161212799315885
11. Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term
studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113:
1243–1251. https://doi.org/10.1007/s00702-005-0385-2
12. Languille S, Blanc S, Blin O, Canale CI, Dal-Pan A, Devau G, Dhenain M,
Dorieux O, Epelbaum J, Gomez D, Hardy I, Henry PY, Irving EA, Marchal J,
Mestre-Frances N, Perret M, Picq JL, Pifferi F, Rahman A, Schenker EI, Terrien
J, Thery M, Verdier JM, Aujard F (2012) The grey mouse lemur: a non-human
primate model for ageing studies. Ageing Res Rev 11:150–162. https://doi.
org/10.1016/j.arr.2011.07.001
13. Blanco MB, Zehr SM (2015) Striking longevity in a hibernating lemur. J Zool
296:177–188. https://doi.org/10.1111/jzo.12230
14. Fischer KE, Austad SN (2011) The development of small primate models for
aging research. ILAR J 52:78–88. https://doi.org/10.1093/ilar.52.1.78
15. Pifferi F, Terrien J, Marchal J, Dal-Pan A, Djelti F, Hardy I, Chahory S,
Cordonnier N, Desquilbet L, Hurion M, Zahariev A, Chery I, Zizzari P, Perret
M, Epelbaum J, Blanc S, Picq J-L, Dhenain M, Aujard F (2018) Caloric
restriction increases lifespan but affects brain integrity in grey mouse lemur
primates. Comm Biol 1:30. https://doi.org/10.1038/s42003-018-0024-8
16. Picq JL, Aujard F, Volk A, Dhenain M (2012) Age-related cerebral atrophy in
nonhuman primates predicts cognitive impairments. Neurobiol Aging 33:
1096–1109. https://doi.org/10.1016/j.neurobiolaging.2010.09.009
17. Silhol S, Calenda A, Jallageas V, MestreFrances N, Bellis M, Bons N
(1996) ß-amyloid protein precursor in Microcebus murinus: genotyping
and brain localization. Neurobiol Dis 3:169–182. https://doi.org/10.1006/
nbdi.1996.0017
18. Mestre-Frances N, Keller E, Calenda A, Barelli H, Checler F, Bons N
(2000) Immunohistochemical analysis of cerebral cortical and vascular
lesions in the primate Microcebus murinus reveal distinct amyloid beta
Gary et al. Acta Neuropathologica Communications           (2019) 7:126 Page 19 of 21
1-42 and beta 1-40 immunoreactivity profiles. Neurobiol Dis 7:1–8.
https://doi.org/10.1006/nbdi.1999.0270
19. Roy M, Cardoso C, Dorieux O, Malgorn C, Epelbaum S, Petit F, Kraska A,
Brouillet E, Delatour B, Perret M, Aujard F, Dhenain M (2015) Age-associated
evolution of plasmatic amyloid in mouse lemur primates: relationship with
intracellular amyloid deposition. Neurobiol Aging 36:149–156. https://doi.
org/10.1016/j.neurobiolaging.2014.07.017
20. Bons N, Mestre N, Petter A (1991) Senile plaques and neurofibrillary changes
in the brain of an aged lemurian primate, Microcebus murinus. Neurobiol
Aging 13:99–105. https://doi.org/10.1016/0197-4580(92)90016-Q
21. Giannakopoulos P, Silhol S, Jallageas V, Mallet J, Bons N, Bouras C, Delaere P
(1997) Quantitative analysis of tau protein-immunoreactive accumulations
and beta amyloid protein deposits in the cerebral cortex of the mouse
lemur, Microcebus murinus. Acta Neuropathol 94:131–139. https://doi.org/1
0.1007/s004010050684
22. Kraska A, Dorieux O, Picq J-L, Petit F, Bourrin E, Chenu E, Volk A, Perret M,
Hantraye P, Mestre-Frances N, Aujard F, Dhenain M (2011) Age associated
cerebral atrophy in mouse lemur Primates. Neurobiol Aging 32:894–906.
https://doi.org/10.1016/j.neurobiolaging.2009.05.018
23. Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez FJ, Pantano P,
Obriot H, Machala C, Anquetil V, Camuzat A, Brice A, Maurage CA, Le Ber I,
Duyckaerts C, Buee L, Sergeant N, Buee-Scherrer V (2016) Reduced tau
protein expression is associated with frontotemporal degeneration with
progranulin mutation. Acta Neuropathol Commun 4:74. https://doi.org/1
0.1186/s40478-016-0345-0
24. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju
S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of
amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer
disease. Neurobiol Dis 24:516–524. https://doi.org/10.1016/j.nbd.2006.08.017
25. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee
L (2006) Alzheimer's disease-like tau neuropathology leads to memory
deficits and loss of functional synapses in a novel mutated tau transgenic
mouse without any motor deficits. Am J Pathol 169:599–616. https://doi.
org/10.2353/ajpath.2006.060002
26. Dhenain M, Chenu E, Hisley CK, Aujard F, Volk A (2003) Regional atrophy in
the brain of lissencephalic mouse lemur primates: measurement by
automatic histogram-based segmentation of MR images. Magn Reson Med
50:984–992. https://doi.org/10.1002/mrm.10612
27. Paxinos G, Franklin KBJ (2001) The Mouse Brain in Stereotaxic Coordinates.
Second Edition, Academic Press, San Diego
28. Picq JL, Villain N, Gary C, Pifferi F, Dhenain M (2015) Jumping stand
apparatus reveals rapidly specific age-related cognitive impairments in
mouse lemur primates. PLoS One 10:e0146238. https://doi.org/10.1371/
journal.pone.0146238
29. Infarinato F, Rahman A, Del Percio C, Lamberty Y, Bordet R, Richardson JC,
Forloni G, Drinkenburg W, Lopez S, Aujard F, Babiloni C, Pifferi F,
Consortium IMIpP (2015) On-going frontal alpha rhythms are dominant in
passive state and desynchronize in active state in adult gray mouse lemurs.
PLoS One 10:e0143719. https://doi.org/10.1371/journal.pone.0143719
30. Rahman A, Languille S, Lamberty Y, Babiloni C, Perret M, Bordet R, Blin
OJ, Jacob T, Auffret A, Schenker E, Richardson J, Pifferi F, Aujard F
(2013) Sleep deprivation impairs spatial retrieval but not spatial learning
in the non-human primate grey mouse lemur. PLoS One 8:e64493.
https://doi.org/10.1371/journal.pone.0064493
31. Bons N, Sihol S, Barbier V, Mestre-Frances N, Albe-Fessard D (1998) A
stereotaxic atlas of the grey lesser mouse lemur brain (Microcebus
murinus). Brain Res Bull 46:1–173. https://doi.org/10.1016/S0361-923
0(97)00458-9
32. Sawiak SJ, Picq JL, Dhenain M (2014) Voxel-based morphometry analyses of
in vivo MRI in the aging mouse lemur primate. Front Aging Neurosci 6:82.
https://doi.org/10.3389/fnagi.2014.00082
33. Ashburner J (2007) A fast diffeomorphic image registration algorithm.
Neuroimage 38:95–113. https://doi.org/10.1016/j.neuroimage.2007.07.007
34. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS
(2001) A voxel-based morphometric study of ageing in 465 normal adult
human brains. Neuroimage 14:21–36. https://doi.org/10.1006/nimg.2001.0786
35. Genovese CR, Lazar NA, Nichols T (2002) Thresholding of statistical
maps in functional neuroimaging using the false discovery rate.
Neuroimage 15:870–878. https://doi.org/10.1006/nimg.2001.1037
36. Rasband WS (1997-2011) ImageJ, U. S, National Institutes of Health,
Bethesda. http://imagej.nih.gov/ij/
37. Diguet E, Petit F, Escartin C, Cambon K, Bizat N, Dufour N, Hantraye
P, Deglon N, Brouillet E (2009) Normal aging modulates the
neurotoxicity of mutant huntingtin. PLoS One 4:e4637. https://doi.
org/10.1371/journal.pone.0004637
38. West MJ, Slomianka L, Gundersen HJG (1991) Unbiased stereological
estimation of the total number of neurons in the subdivisions of the rat
hippocampus using the optical fractionator. Anat Rec 231:482–497. https://
doi.org/10.1002/ar.1092310411
39. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer's
disease in individuals under thirty. Acta Neuropathol 121:171–181. https://doi.
org/10.1007/s00401-010-0789-4
40. Caillierez R, Begard S, Lecolle K, Deramecourt V, Zommer N, Dujardin
S, Loyens A, Dufour N, Auregan G, Winderickx J, Hantraye P, Deglon
N, Buee L, Colin M (2013) Lentiviral delivery of the human wild-type
tau protein mediates a slow and progressive neurodegenerative tau
pathology in the rat brain. Mol Ther 21:1358–1368. https://doi.org/1
0.1038/mt.2013.66
41. Jack CR Jr, Knopman DS, Chetelat G, Dickson D, Fagan AM, Frisoni GB,
Jagust W, Mormino EC, Petersen RC, Sperling RA, van der Flier WM,
Villemagne VL, Visser PJ, Vos SJ (2016) Suspected non-Alzheimer disease
pathophysiology - concept and controversy. Nat Rev Neurol 12:117–124.
https://doi.org/10.1038/nrneurol.2015.251
42. Monsell SE, Kukull WA, Roher AE, Maarouf CL, Serrano G, Beach TG,
Caselli RJ, Montine TJ, Reiman EM (2015) Characterizing
apolipoprotein E epsilon 4 carriers and noncarriers with the clinical
diagnosis of mild to moderate Alzheimer dementia and minimal beta-
amyloid peptide plaques. Jama Neurol 72:1124–1131. https://doi.org/1
0.1001/jamaneurol.2015.1721
43. Deng W, Aimone JB, Gage FH (2010) New neurons and new memories:
how does adult hippocampal neurogenesis affect learning and memory?
Nat Rev Neurosci 11:339–350. https://doi.org/10.1038/nrn2822
44. Bird CM, Burgess N (2008) The hippocampus and memory: insights from spatial
processing. Nat Rev Neurosci 9:182–194. https://doi.org/10.1038/nrn2335
45. McDonald RJ, King AL, Wasiak TD, Zelinski EL, Hong NS (2007) A complex
associative structure formed in the mammalian brain during acquisition of a
simple visual discrimination task: dorsolateral striatum, amygdala, and
hippocampus. Hippocampus 17:759–774. https://doi.org/10.1002/hipo.20333
46. Ranganath C, Ritchey M (2012) Two cortical systems for memory-guided
behaviour. Nat Rev Neurosci 13:713–726. https://doi.org/10.1038/nrn3338
47. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS,
Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS,
Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological
processes in Alzheimer's disease: an updated hypothetical model of
dynamic biomarkers. Lancet Neurol 12:207–216. https://doi.org/10.1016/
S1474-4422(12)70291-0
48. Rosen RF, Tomidokoro Y, Farberg AS, Dooyema J, Ciliax B, Preuss TM,
Neubert TA, Ghiso JA, LeVine H 3rd, Walker LC (2016) Comparative
pathobiology of beta-amyloid and the unique susceptibility of humans to
Alzheimer's disease. Neurobiol Aging 44:185–196. https://doi.org/10.1016/j.
neurobiolaging.2016.04.019
49. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier
JG, Hauw JJ, Rossier J, Dormont D (1997) Transmission of the BSE agent to
mice in the absence of detectable abnormal prion protein. Science 275:
402–405. https://doi.org/10.1126/science.275.5298.402
50. Caughey B, Baron GS, Chesebro B, Jeffrey M (2009) Getting a grip on
prions: oligomers, amyloids, and pathological membrane interactions.
Annu Rev Biochem 78:177–204. https://doi.org/10.1146/annurev.
biochem.78.082907.145410
51. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:
101–112. https://doi.org/10.1038/nrm2101
52. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR,
Kayed R (2011) Tau oligomers impair memory and induce synaptic and
mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6:39.
https://doi.org/10.1186/1750-1326-6-39
53. d'Orange M, Auregan G, Cheramy D, Gaudin-Guerif M, Lieger S,
Guillermier M, Stimmer L, Josephine C, Herard AS, Gaillard MC, Petit F,
Kiessling MC, Schmitz C, Colin M, Buee L, Panayi F, Diguet E, Brouillet
E, Hantraye P, Bemelmans AP, Cambon K (2018) Potentiating tangle
formation reduces acute toxicity of soluble tau species in the rat.
Brain 41:535–549. https://doi.org/10.1093/brain/awx342
Gary et al. Acta Neuropathologica Communications           (2019) 7:126 Page 20 of 21
54. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ,
Kiritoshi T, Neugebauer V, Jackson GR, Kayed R (2012) Alzheimer brain-derived
tau oligomers propagate pathology from endogenous tau. Sci Rep 2:700
55. Di Fede G, Catania M, Maderna E, Ghidoni R, Benussi L, Tonoli E, Giaccone
G, Moda F, Paterlini A, Campagnani I, Sorrentino S, Colombo L, Kubis A,
Bistaffa E, Ghetti B, Tagliavini F (2018) Molecular subtypes of Alzheimer's
disease. Sci Rep 8. https://doi.org/10.1038/S41598-018-21641-1
56. Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach
O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D (2019) A
oligomer elimination restores cognition in transgenic Alzheimer's mice
with full-blown pathology. Mol Neurobiol 56:2211–2223. https://doi.
org/10.1007/s12035-018-1209-3
57. Festing M, Altman D (2002) Guidelines for the design and statistical analysis
of experiments using laboratory aminals. (erratum in ILAR J. 2005;46(3):320.).
ILAR J 43:244–258. https://doi.org/10.1093/ilar.43.4.244
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Gary et al. Acta Neuropathologica Communications           (2019) 7:126 Page 21 of 21
1 
 
Encephalopathy induced by Alzheimer brain inoculation 
in a non-human primate 
 
Charlotte Gary, Suzanne Lam, Anne-Sophie Hérard, James E. Koch, Fanny Petit, Pauline 
Gipchtein, Stephen J. Sawiak, Raphaëlle Caillierez, Sabiha Eddarkaoui, Morvane Colin, 
Fabienne Aujard, Jean-Philippe Deslys, French Neuropathology Network, Emmanuel 
Brouillet, Luc Buée, Emmanuel E. Comoy, Fabien Pifferi, Jean-Luc Picq, Marc Dhenain
 
 
Supplementary data 
Supplementary Tables 
Patient 
Braak 
and 
Braak 
stage 
Thal 
phase 
Age 
(years) 
Post-mortem 
delay (hours) 
Immunohistochemistry 
AD1 VI 5 76 10 
Tau-positive 
(AT8, Innogenetic, 1/500) 
Aβ-positive, including amyloid 
angiopathy (6F3D, Dako, 1/200) 
Alpha-synuclein-negative 
(LB509, Zymed, 1/250) 
AD2 VI 4 83 21 
Tau-positive 
(AT8, Innogenetic, 1/500) 
Aβ-positive, without amyloid 
angiopathy (6F3D, Dako, 1/200) 
Alpha-synuclein 
negative (LB509, Zymed, 1/250) 
CTRL 0 0 69 6 
Tau-negative 
(AT8, Innogenetic, 1/500) 
Aβ-negative 
(6F3D, Dako, 1/200) 
Alpha-synuclein-negative 
(LB509, Zymed, 1/250) 
 
Suppl. Table 1 Human brain sample characteristics and staging. Human parietal cortex 
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samples were obtained from two Alzheimer’s patients (AD1 and AD2) and one control 
(CTRL) individual. They were tested for several pathologies by the French reference 
laboratory (C. Duyckaerts, Pitié-Salpêtrière hospital, Paris, France). Only the Alzheimer 
brains presented Alzheimer lesions. No other pathologies were detected in the brains. 
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Experimental protocol 
Before 
inoculation 
3 
mpi 
6 
mpi 
9 
mpi 
12 
mpi 
15 
mpi 
18 
mpi 
Rotarod test X  X  X  X 
Learning tasks X  X  X  X 
Long-term memory tasks   X  X  X 
Electroencephalography X  X  X   
MRI and atrophy evaluation X X X X X X X 
Immunohistochemistry       X 
Stereological evaluation of 
neuronal loss (NeuN) 
      X 
Evaluation of amyloid (4G8) 
and tau (AT8, MC1, AT100) 
lesions 
      X 
Suppl. Table 2 Schedule of the experimental protocol. mpi: months post-inoculation. MRI: 
magnetic resonance imaging. 
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Brain 
regions 
SSF 
 
NES 
 
ACF 
(µm²) 
x-y steps 
(µm) 
ASF 
 
TSF-µm 
mean±SEM 
CE 
mean±SEM 
Sampled cells 
per animal 
CA1/2 1/10 7-10 30*30  50-50 0.36 11.63±0.03 0.037±0.002 430-700 
CA3 1/10 5-7 30*30   50-50 0.36 11.63±0.03 0.064±0.002 485-760 
EC-I 1/10 6 100*100  150-150 0.44 12.21±0.10 0.067±0.001 90-170 
EC-II 1/10 6 30*30  75-75 0.16 12.21±0.10 0.073±0.000 400-530 
EC-III-VI 1/10 6 50*50  150-150 0.11 12.21±0.10 0.064±0.000 650-800 
Cing/RS 1/10 5-8 50*50 150-150 0.11 11.59±0.07 0.056±0.001 1600-2500 
Suppl. Table 3 Sampling parameters for stereological counting of NeuN-positive neurons. 
SSF: Section sampling fraction; NES: Number of evaluated sections; ACF: Area of counting 
frames; x-y steps: x-y steps between each counting frame; ASF: Area of the sampling 
fractions; TSF: Thickness of the sampling fraction; CE: Coefficient of error; CA1/2: CA1/2 
region of the hippocampus; CA3: CA3 region of the hippocampus; EC-1, EC-2, EC-III-VI: 
Layers I, II, III-VI of the entorhinal cortex; Cing/RS: Cingulate cortex/retrosplenial cortex.  
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Brain regions 
Cluster size 
(voxels) 
Peak p-value 
FDR-corrected 
Peak 
T value 
 
Entorhinal cortex, amygdala, hippocampus and inferior 
temporal cortex 
1562 *** 0.0004 6.3952 
Cingulate and retrosplenial cortices 1342 *** 0.0004 6.3777 
Diagonal band of Broca, fornix and nucleus and stria 
terminalis 
184 ** 0.0013 5.7422 
Ventral hippocampus 103 * 0.0109 4.2790 
Caudate nucleus 70 ** 0.0059 4.8479 
Entorhinal cortex 59 * 0.0117 4.2231 
Lateral temporal cortex 55 ** 0.0062 4.7998 
Peri-third ventricule area 52 * 0.0112 4.2488 
Inferior temporal cortex 47 * 0.0175 3.8968 
Fornix and stria terminalis 33 ** 0.0061 4.8140 
Parietal cortex 31 ** 0.0045 5.0162 
Amygdala 30 * 0.0102 4.4005 
Lateral temporal cortex 23 * 0.0221 3.6795 
Amygdala 22 * 0.0267 3.4984 
Parietal cortex 18 * 0.0227 3.6538 
Amygdala 18 * 0.0255 3.5305 
Inferior temporal cortex 17 * 0.0221 36785 
Caudate nucleus 16 ** 0.0067 4.7113 
Fornix 15 * 0.0172 3.9105 
Inferior temporal cortex 15 * 0.0193 3.7971 
Caudate nucleus 14 * 0.0233 3.6270 
Inferior temporal cortex 13 * 0.0234 3.6142 
Inferior temporal cortex 13 * 0.0140 4.0705 
Entorhinal cortex 11 * 0.0135 4.1200 
Parietal cortex 10 * 0.0108 4.3009 
Amygdala 10 * 0.0255 3.5285 
Suppl. Table 4 Brain regions with gray matter loss in the Alzheimer's disease-inoculated 
group relative to the control-inoculated group. N = 6 animals per group at 0, 3, 6, 9 mpi and n 
= 6 and 4 in the Alzheimer- and control-inoculated groups, respectively at 12, 15, and 18 mpi. 
*p < 0.05; **p < 0.01; ***p < 0.001.  
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Species Measure mpi Sample 
size 
Tau30
+/+
 mice Tau deposition in the soma of hippocampal neurons 1 1 
APP/PS1dE9 mice Aβ deposition in the hippocampus 4 8 
Mouse lemurs Learning task D2 6 249 
Mouse lemurs Learning task D3 12 10 
Mouse lemurs Learning task D4 18 13 
Mouse lemurs Memory Task D1r 6 1 
Mouse lemurs Memory task D2r 12 3 
Mouse lemurs Memory task D3r 18 2 
Mouse lemurs EEG Delta 6 mpi 6 3 
Mouse lemurs EEG Theta 6 mpi 6 4 
Mouse lemurs EEG Delta 12 mpi 12 4 
Mouse lemurs EEG Theta 12 mpi 12 9 
Mouse lemurs EEG Alpha 12 mpi 12 3 
Mouse lemurs EEG Sigma 12 mpi 12 3 
Mouse lemurs EEG Beta 12 mpi 12 3 
Mouse lemurs NeuN-CA3 18 5 
Mouse lemurs NeuN-CA1-2 18 1067 
Mouse lemurs NeuN-EC-III-VI 18 8 
Mouse lemurs NeuN-EC-II 18 7 
Mouse lemurs NeuN-EC-I 18 52 
Mouse lemurs NeuN-Cg/RS 18 46 
Mouse lemurs Aβ deposition in the brain 18 3 
Mouse lemurs CAA in the brain 18 35 
Mouse lemurs Tau deposition in the brain 18 15 
 
Suppl. Table 5 Estimated sample size to compare control and Alzheimer-inoculated mice and 
mouse lemurs assuming a significance level of 5%, a power of 80%, and two-sided tests. The 
different effects were classified according to species (Tau30+/+ mice, APP/PS1dE9 mice or 
mouse lemurs). mpi represents the time post inoculation for the measure. Sample size 
represents the number of animal per experimental arm. 
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Supplementary Figures 
 
Suppl. Fig. 1 Cognitive test in mouse lemurs. a Pairwise visual discrimination task jumping-
stand apparatus. Lemurs had to jump from a central platform to one of two boards that 
displayed different visual stimuli. One board gave access to a positive outcome (nest 
containing a reward) and the other led to a negative (and non-rewarding) outcome (fall). An 
increasing number of trials required to achieve the criterion indicates a performance decline. 
b Schematic overview of the cognitive tasks. A learning task was performed before 
inoculation (0 months post-inoculation (mpi)). Long-term memory tasks consisted of the 
repetition of the discrimination task learned six months before. New learning tasks involving 
novel pairs of stimuli were performed every six months, after long-term memory tasks (black 
arrows: six months after; gray arrows: one day after). 
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(Aβ1-42 values updated 2019-12-03) 
Suppl. Fig. 2 Characterization of human brain samples and homogenates. a-e 
Immunohistochemical staining (6F3D antibody) for Aβ in the two Alzheimer samples (a-d) 
and the control sample (g). a One subject (AD1) displayed amyloid angiopathy. The 
arrowhead points to a capillary, wall of which is immunoreactive for Aβ. The black arrow 
points to a small artery with severe amyloid angiopathy, sometimes forming parenchymal 
deposits. b The second patient (AD2) displayed numerous senile plaques, diffuse and stellate 
deposits. A vessel without amyloid deposition is seen in the middle of the field (black 
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arrows). No amyloid angiopathy was detected in that case. c-d Other sections from AD1 (c) 
and AD2 (d) showing amyloid plaques (black arrows). Arrow heads (in c) correspond to 
amyloid angiopathy. e-f, h Immunohistochemical staining (polyclonal anti-tau antibody) for 
tau lesions of the same samples. Tau positive NFTs are indicated with arrows in the two 
Alzheimer samples (e-f). Most of the brown labelling corresponds to neuropil threads. 
Amyloid or tau lesions were not detected in the control subject (g, h). i-l Biochemical 
characterization of human brain homogenates. Aβ1-42 (i) Aβ1-40 (j) were only detected in 
Alzheimer brain homogenates (20% weight/volume, ELISA). The AD1 patient that displayed 
more amyloid angiopathy also had more Aβ1-40 than AD2. k Typical shift of tau-Cter triplets 
in the Alzheimer samples relative to control sample (western blot, black arrows) (Papegaey A 
et al., Acta Neuropathol Commun 2016, 4: 74. https://doi.org/10.1186/s40478-016-0345-0). 
Arrow head corresponds to GAPDH loading reference. (l) Pathological pS396-positive tau 
smears were only detected in Alzheimer samples (western blot). Graphs display median and 
interquartile interval. Scale bars: 50 µm. 
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Suppl. Fig. 3 Prion protein examination in human brain samples. Western blot patterns of 
PrPres from control (CTRL) and Alzheimer (AD) brain samples displayed no signs of PrPres 
pathology. T2A, PrPres type 2A control from a patient with sporadic CJD; T1, PrPres type 1 
control from a patient with sporadic CJD; T2B, PrPres type 2B control from a patient with 
variant CJD (Parchi P et al., Ann Neurol 1999, 46: 224-233.1999, 
https://doi.org/10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W). 
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Suppl. Fig. 4 Aβ and Tau pathology in mice after inoculation with human brain homogenates. 
a-c Acceleration of Aβ deposition (arrow) in the hippocampus of an Alzheimer-inoculated 
APP/PS1∆E9 mouse (b) four months after inoculation compared to a control-inoculated mouse 
(a) (Bam10 staining, n = 6 and 16 control- and Alzheimer-inoculated mice, respectively). c 
Quantification of the Aβ load, showing greater amyloid load in the Alzheimer-inoculated 
group than in control-inoculated mice. Animals inoculated with the brain presenting with 
amyloid angiopathy (AD1) had a higher amyloid load than the mice inoculated with the brain 
without angiopathy (AD2) (p = 0.01). d-f Acceleration of tau deposition in the hippocampus 
of an Alzheimer-inoculated Tau30
+/+
 mouse (e) one month after inoculation compared to a 
control-inoculated mouse (d) (AT8 staining, n = 5 and 10 control- and Alzheimer-inoculated 
animals, respectively). f Quantification of the density of Tau-positive somas showed more tau 
deposition in the Alzheimer-inoculated Tau30
+/+
 mice than control-inoculated mice. g-i 
Similar GFAP staining in control- (g) and Alzheimer-inoculated (h) APP/PS1∆E9 mice four 
months after inoculation (n = 6 and 16 control- and Alzheimer-inoculated animals, 
respectively). j-l Similar Iba-1 staining in control- (j) and Alzheimer-inoculated (k) 
12 
 
APP/PS1∆E9 mice four months after inoculation (n = 6 and 16 control- and Alzheimer-
inoculated animals, respectively). *p < 0.05, ***p < 0.001, Mann-Whitney tests. Scale bars: 
main images: 500 µm; insets: 50 µm. Scatter plots display median and interquartile interval. 
CTRL-inoculated animals are in blue, AD1-inoculated in green and AD2-inoculated in red. 
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Suppl. Fig. 5 Correlation between cognitive abilities and EEG delta frequency. Delta 
frequency measured by EEG at 6 mpi inversely correlated with long-term memory 
performance (Spearman's rank correlation test). n = 6 animals per group. CTRL-inoculated 
animals are in blue, AD1-inoculated in green and AD2-inoculated in red. 
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Suppl. Fig. 6 Time-dependent evolution of cerebral atrophy in inoculated lemurs. Rate of 
atrophy evolution in Alzheimer- relative to control-inoculated animals between baseline and 
6 mpi (a-d), 6 mpi and 12 mpi (e-h), and 12 mpi and 18 mpi (i-l). 3D representations of 
atrophy rates between each time slot are presented in d (baseline to 6 mpi, green), h (6 to 12 
mpi, orange), i (12 to 18 mpi, red). m-p show all the time slots on the same 3D views. a-d 
The atrophy process was low from baseline to 6 mpi, suggesting a limited acute effect 
induced by Alzheimer-brain inoculation. It involved mostly the amygdala and the ventral 
portion of the retrosplenial cortex. Rate of atrophy was low in the posterior cingulate cortex 
15 
 
at this stage. e-h The atrophy rate was maximal from 6 to 12 mpi. At this stage, it continued 
to involve the amygdala, the retrosplenial cortex in a more dorsal area and also reached the 
hippocampus, and the posterior cingulate cortex. i-l Evolution of the atrophy process was 
more limited from 12 to 18 mpi and involved mainly the retrosplenial cortex and the 
posterior cingulate cortex. EC: entorhinal cortex; Am: amygdala; Hip: hippocampus; PC: 
posterior cingulate cortex; RS: retrosplenial cortex. The colored scale represents group-wise 
differences in percentage local volume loss relative to baseline, calculated from the Jacobian 
determinants of the image registration parameters. 
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Suppl. Fig. 7 Impact of tau pathology on memory and neuronal loss. The group of animals 
inoculated with Alzheimer brains was split into those displaying tau lesions and those without 
tau lesions. The two tau-positive animals had the worst memory score at 18 months (a) as 
well as the lowest neuronal counts in the CA3 region of the hippocampus (b). CTRL-
inoculated animals are in blue, AD1-inoculated in green and AD2-inoculated in red. 
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Suppl. Fig. 8 Similar level of intracellular 4G8-positive structures in Alzheimer’s disease 
and control-inoculated lemurs. Immunostaining with 4G8 in the hippocampus of Alzheimer’s 
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disease- (a-c) and control-inoculated animals (f-h) showing intracellular labelling in both 
groups. Quantification of intracellular labelling did not show any difference in the 
hippocampus (e) or in the whole brain (j). d-i shows the same staining in an Alzheimer’s 
disease-inoculated animal in the absence of primary antibody. Intracellular structures were 
not detected when the primary antibody was omitted. Scale bars: 100 µm (a, f, d); 50 µm (b-
c, g-i). Scatter plots display median and interquartile interval. CTRL-inoculated animals are 
in blue, AD1-inoculated in green and AD2-inoculated in red. 
 
